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Porcine reproductive and respiratory syndrome (PRRS) is an economically significant
panzootic affecting the swine industry worldwide. The genetic and antigenic variation of existing
PRRS virus (PRRSV) strains and constantly evolving characteristic of PRRSV present great
challenges for the development of effective vaccines and treatments against heterologous
PRRSV strains. In this study, we investigated novel approaches to combatting the PRRS
panzootic.
The scavenger receptor CD163 has been reported as indispensable for PRRSV infection.
Thus, in our study, porcine CD163 receptor was regarded as a valuable target for inhibition of
PRRSV infection. Two antiviral approaches were investigated 1) downregulating CD163
expression in porcine alveolar macrophages (PAMs), and 2) blocking the protein-protein
interactions (PPIs) between PRRSV and porcine CD163.
In the first approach, we validated that the interleukin 10 (IL-10) stimulated Janus kinase
(JAK)-signal transducer and activator of transcription 3 (STAT3) signaling also upregulated
CD163 expression in pig cells as it does in humans. We tested 3 STAT3 inhibitors validated
previously and identified cryptotanshinone (Cpt), a natural compound extracted from the herb
Salvia miltiorrhiza (Danshen), as an efficient inhibitor of IL-10 stimulated and basal level of
CD163 expression in PAMs. We further found Cpt was able to suppress infection of PAMs by
type I and type II PRRSV.

Chang Huang – University of Connecticut, 2020

In the second approach, we established specific bimolecular fluorescence
complementation (BiFC) assays to study PPIs between PRRSV glycoprotein GP2a or GP4 and
the fifth scavenger receptor cysteine-rich domain (SRCR5) of porcine CD163. Using one BiFC
assay, we tested 74 chemical compounds predicted to bind with porcine CD163-SRCR5 domain
obtained by a structure-based virtual screening program. We identified one synthetic compound
(4-Fluoro-2-methyl-N-[3-(3-morpholin-4-ylsulfonylanilino)quinoxalin-2yl]benzenesulfonamide, C25H24FN5O5S2), designated herein as B7, efficiently blocked the PPI
between PRRSV GP2a/GP4 and porcine CD163-SRCR5 domain. We found compound B7 was
able to substantially inhibit infection of PAMs by type I and type II PRRSV in vitro. We further
characterized some B7 analogues in vitro and identified some small molecules with similar
antiviral efficacy as B7. We also proposed that 3-(morpholinosulfonyl)anilino moiety of B7 or
the 3-(piperidinylsulfonyl)anilino moiety of a B7 analogue could be pharmacophore important
for the anti-PRRSV activity.
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Chapter 1. Literature Review
1.1

PRRSV relevance
Porcine reproductive and respiratory syndrome (PRRS) was first reported as an

unrecognized and catastrophic disease in the U.S. in 1987 (Keffaber, 1990) and then in Germany
in 1990 (Wensvoort et al., 1992). The disease is characterized by reproductive disorder of sows
and respiratory syndrome of piglets and growing pigs (Zimmerman et al., 2012). Clinical signs
of reproductive disorder are decline in milk yield/agalactia in sows, late-term abortion and early
or delayed farrowing that contain dead and mummified fetuses, stillborn pigs, and weak-born
piglets. The respiratory syndrome is recognized by coughing, pneumonia, fever, and anorexia
(Goyal, 1993). The PRRS etiology was first resolved by researchers at the Central Veterinary
Institute (Lelystad, the Netherlands) and designated as Lelystad virus after fulfillment of Koch’s
postulates (Terpstra et al., 1991). Shortly thereafter, the causative virus responsible for the
outbreak in the U.S. was isolated and designated as American Type Culture Collection VR-2332
(ATCC VR-2332) (Benfield et al., 1992). Later characterization of PRRS virus (PRRSV) strains
originated in Europe (type I) and North America (type II) demonstrated striking genetical
divergence. In the following years the disease has become an epizootic in most swine-producing
regions. An “atypical” or “acute” variant first appeared in Iowa, United States in the mid 1990s
(Mengeling et al., 1998). In 2001, an abrupt appearance of a highly virulent PRRSV strain
named MN184 occurred in Minnesota, USA (Han et al., 2006). In 2006, the emergence of the
notable highly-pathogenic PRRSV (HP-PRRSV) in China affected over 2 million pigs and
caused about 400,000 fatalities (Tian et al., 2007). Control of PRRS is problematic and during
the past 2 decades, PRRS has become one of the most economically significant diseases
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affecting swine industry, costing $664 Million to the United States annually (Holtkamp et al.,
2013).

1.2

PRRS prevention and control
PRRS prevention includes any practice to preclude either the introduction of PRRSV into

naive herds or the introduction of new PRRSV strains into positive herds. Pig repopulation and
semen for artificial insemination constitute the major source of PRRSV to a herd (Le Potier et
al., 1997). Semen should be routinely tested using a PCR-based assay prior to its used in
artificial insemination. All replacement breeding stocks are required to originate from a large
unit tested PRRSV negative. In addition, the replacement stock should be under quarantine for at
least 30 days and then tested for PRRSV load before introduced to the breeding herd
(Zimmerman, 2006). All the movement of inputs and outputs from the farms, e.g. feed delivery,
manure removal, personnel activity, entry or other animals, and entry of air/water, hold the
potential to carry virus into a herd (Zimmerman et al., 2019). Biosecurity efforts can be taken to
prevent PRRSV importation. These precautionary actions include transport vehicle sanitation
and drying, personnel behaviors in accordance with entry protocols (e.g. shower-facilities and
Danish entry system), and insect control programs (e.g. screens, habitat management, and
insecticides) (Zimmerman et al., 2019). For dense-populated pig barns, air filtration may be used
to prevent PRRSV, which is also shown to reduce the introduction of other airborne pathogens,
such as Mycoplasma hyopneumoniae (Otake et al., 2010; Spronk et al., 2010).
Efforts to treat PRRS efficiently fail. Most practices of PRRS control are aiming to limit
the adverse effects caused by PRRSV in various production stages. During an acute outbreak,
antibiotics, e.g. Tetracycline, Penicillin, and Trimethoprim-sulfonamide, are administered to
ameliorate secondary infection caused by bacterial pathogens (Aarestrup et al., 2008). Consistent
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acclimatization of the incoming replacement gilts constitutes an important part of any efficient
PRRSV control program. The objective of these efforts is to confer protective immunity to the
gilts and lower the incidence of PRR outbreak after the introduction of these gilts to the breeding
herd. The initial step of gilt acclimatization is to confine the gilts in designated facilities for gilt
development unit as many production systems perform (Dee et al., 1997). During the 4 to 6month period before they enter the breeding herd, replacement gilts develop protective immunity
activated by MLVs, or by farm-specific wild-type virus in the form of live virus inoculation
(LVI). LVI typically involves inoculating gilts with serum collected from acutely infected pigs
since the serum contains farm-specific PRRSV strains (Zimmerman et al., 2019). Note that the
method is inherently risky primarily because the safety and efficacy of this procedure has not
been well characterized like commercial MLVs. Therefore, it is important to measure the viral
load in the serum and administer a standardized dose, as well as validate the absence of some
hazardous agents in the serum prior to administration. In addition, whole herd vaccination has
been applied to immunize subpopulations of naïve pigs (Dee et al., 1996). Application of whole
herd vaccination has been reported to reduce the time taken before the yield of a breeding herd
producing PRRSV-negative weaned piglets, and to improve biological and financial performance
of the chronically infected herd (Linhares et al., 2014).
Apart from gilt acclimation, PRRSV eradication from a herd is also essential for an
efficient PRRS control program. Chances that PRRSV is eliminated spontaneously from a herd
are remote, creating problems for consistent PRRS control. Several methods have been used to
eliminate PRRSV from a herd, including total depopulation/repopulation, partial
depopulation/repopulation, test and removal, and herd closure (Corzo et al., 2010). Applications
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of these methods to achieve successful PRRSV elimination are case-by-case, depending on
immune status of a herd, unit size, cost, and stages of production, etc.
Total herd depopulation and repopulation is very efficient but costly. This method is
justifiably prioritized on occasions when the farrow-to finish herds are inflicted with PRRSV
infection, and when elimination of concurrent infection caused by other pathogens is required,
both of which collaborate to make elimination of the virus via other methods inefficient
(Zimmerman, 2006). Partial depopulation, on the other hand, is usually used to eliminate PRRSV
from a growing herd which is largely PRRSV negative. When used in a large unit (>500 sows),
additional methods (e.g. herd enclosure or test-and-removal) are recommended to eradicate
PRRSV from the breeding herd prior to attempting elimination in the pig flow (Zimmerman,
2006).
During operation of herd closure, all the pigs previously exposed to PRRSV are enclosed
without any introduction of replacement animals to the herd, prior to complete elimination of the
virus from the herd. This practice is based on the fact that though PRRSV exists persistently in
the immunized herd, it will eventually be eradicated by the immune system of the pig
(Torremorell and Conroy, 2003). Since an immune population will undergo persistent infection
before PRRSV extinction, a long period of enclosure is required. As a rule of thumb, a 6-month
period is recommended while the period can be variable depending on the status of the farm and
pig flow. After the elimination of the virus from the enclosed herd, replacement pigs originated
from a negative herd are then introduced following attrition or scheduled culling of the
previously infected pigs (Zimmerman et al., 2019).
Candidate herds for test-and removal include herds with an estimated prevalence under
25%, more than 12 months since the last clinical observation of PRRS, and segregated
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production (Zimmerman, 2006). Test-and-removal is recommended for herds where there is no
indication of PRRSV recirculation in the herd, and where the presence of pigs with persistent
infection still poses potential threat to the PRRS control program. PRRSV elimination through
test-and removal involves testing blood samples of the breeding herd, identifying PRRSV
positive pigs by testing antibody and virus, and culling infected pigs from the herd (Dee et al.,
2004; Dee and Philips, 1998).

1.3

PRRS virion and genome structure
The causative agent of PRRS is PRRSV which belongs to the family Arteriviridae, order

Nidovirales. Other viral species of the family Arteriviridae include lactate dehydrogenaseelevating virus (LDV), equine arteritis virus (EAV), and simian hemorrhagic fever virus (SHFV)
(Dunowska et al., 2012; King et al., 2011; Plagemann and Moennig, 1992). PRRSV is an
enveloped, single-stranded, and positive sense RNA virus. The virion has a genome of 14.9 kb to
15.5 kb packed by a proteinaceous nucleocapsid surrounded by a lipid membrane, the envelope
where five or six structural proteins are embedded (Figure 1.1B). The virion has a spherical to
oval shape with a size ranging from about 50 to 70 nm in diameter (Spilman et al., 2009).
The PRRSV genome encodes a 5’-untranslated region (5’UTR) of 217-222 nucleotides in
type I genotype and 188-191 nucleotides in type II genotype (King et al., 2011; Yun and Lee,
2013). The genome contains 10 known open reading frames (ORFs). The downstream of 5’UTR
has the large overlapping replicase ORFs which are situated in the first three fourths of the
PRRSV genome (Kappes and Faaberg, 2015). The large ORFs consist of ORF1a and ORF1b
which share a single translational start site but conclude translation at two different ribosomal
frame shift sites (Fang et al., 2012) (Figure 1.1.A). The ORF1a and ORF1b regions encode four
large nonstructural polyproteins, pp1a, pp1a-nsp2N, pp1a-nsp2TF, and pp1ab which are
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subsequently processed into at least 14 nonstructural proteins. These nonstructural proteins have
a wide range of functions including potential interferon (IFN) antagonism, forming replication
and transcription complex (RTC), membrane modification, and RNA-dependent RNA
polymerase (Lunney et al., 2016). ORFs 2a, 2b, and 3 to 7 only make up approximately one
fourth of the viral genome at the 3’ end, and they encode the viral structural proteins,
specifically, glycoprotein 2a (GP2a), GP3, GP4, GP5, protein E, the matrix protein (M), and the
nucleocapsid protein (N), respectively (Wu et al., 2005) (Figure 1.1.B). Protein M and protein E
are non-glycosylated while GP2a, GP3, GP4, and GP5 are N glycosylated envelope proteins
(Dea et al., 2000). GP5 is the most abundant glycoprotein on the viral envelope, hence its name
the major envelope glycoprotein. By contrast, the GP2a, GP3, and GP4 proteins only constitute a
small proportion of the envelope glycoproteins, and are therefore classified as the minor
envelope glycoproteins (Das et al., 2010).

1.4

PRRSV taxonomy and classification
The European (EU) and North American (NA) isolates belong to 2 genetically distinct

genotypes, and were later officially designated as Type I (PRRSV-1, EU genotype) and Type II
(PRRSV-2, NA genotype) PRRSV. Lelystad and VR-2332 strains, both discovered in 1991, are
the prototype wildtype parental strains of PRRSV-1 and PRRSV-2, respectively. Nucleotide
sequence analysis indicates the 2 genotypes vary by approximately 44%. Furthermore,
phylogenetic analyses largely based on ORF5 demonstrate remarkable divergence between the 2
PRRSV genotypes. Comparative analyses of the nucleotide sequence show the sequence
variation is up to 30% among representative PRRSV-1 strains and exceeds 21% among PRRSV2 strains (Zimmerman et al., 2019). The extraordinarily diverse genetic composition may be
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primarily due to the lack of PRRSV RNA-dependent RNA polymerase proofreading and
tremendous viral recombination (Keffaber, 1989).
Though these 2 PRRSV genotypes distinct substantially, molecular clock analysis shows
PRRSV-1 and PRRSV-2 can be originated from a common ancestor that existed at least 100
years ago, but evolved independently in geographically or ecologically distinct environments
since then, in a yet-to-be-identified host (Forsberg, 2005). PRRSV-1 has further been divided
into 4 subtypes. PRRSV-1 subtype 1 to which Lelystad virus belongs, is prevalent in the whole
Europe, while PRRSV-1 subtype 2, 3, and 4 are primarily present in Eastern Europe (Stadejek et
al., 2013). Phylogenetic analysis based on ORF5 of PRRSV-1 subtype 1 strains, identified 12
diverse linages while 9 distinct lineages have been defined by ORF5 phylogeny of PRRSV-2
(Hasita et al., 2010; Shi et al., 2010). Seven lineages of PRRSV-2 are mostly present in North
America while the other 2 lineages are only prevalent in East Asia. The PRRSV-2 outbreaks in
Asia seem to occur primarily due to introductions of the North American lineages followed by
local evolution (Hu et al., 2009; Zhao et al., 2015). The genomes of existing PRRSV field
isolates are also constantly evolving with a higher rate (order of 10-2/site/year) than the estimated
rate (10-3 to 10-5/site/year) for other RNA viruses (Hanada et al., 2005). Considerable genetic
variations among PRRSV strains consequently leads to differences in virulence and
pathogenesis. Some strains only cause subclinical infection to farms while more pathogenic
strains, like Lena strain in Type I and HP-PRRSV in Type II in China, afflict swine herd with
high mortality (Karniychuk et al., 2010; Tian et al., 2007).

1.5

Viral infectivity
PRRSV causes persistent infection to carrier animals. A susceptible and infected pig

usually undergoes 3 distinct stages before PRRSV is cleared from the body: acute infection,
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persistence, and extinction, each of which demonstrates unique immunology, virology, and
clinical disease. The acute infection occurs when the pig is infected with PRRSV at the initial
stage and the virions replicate primarily in the dendritic cells and macrophages in the upper
respiratory tract and the lungs, respectively. Then viremia occurs 6-12h post infection. Viremia
may last for several weeks before virus is no longer detectable in blood and lungs. Then the
infection proceeds to the second stage of persistent infection during which the infected pig is
majorly asymptomatic. At this phase, viral replication primarily occurs in lymphoid organs,
including tonsil and lymph nodes but not spleen (Allende et al., 2000; Rowland et al., 2003;
Wills et al., 1997a). During this process, the continuously replicating virus may be shed through
oral and nasal secretions (Wills et al., 1997a), urine (Wills et al., 1997b), semen (Swenson et al.,
1994), and occasionally feces (Christianson et al., 1993). Virus shedding from persistently
infected pigs is one of the most unsettling respects of PRRSV infection adding to the difficulties
in efficient control of viral infection in the field. Subsequently, the virus presence progressively
decline until the virions are eliminated from the host. The eventual disappearance of virus marks
the final stage of infection, the extinction. The duration that PRRSV replication can be
maintained may be up to 250 days, and this figure differs from pig to pig (Wills et al., 2003).
Swine is the only known natural host of PRRSV. In vivo, the virus has a very narrow
tropism, only causing reproductive infection to cells of monocyte macrophage system. The fully
differentiated porcine alveolar macrophages (PAMs) are considered the primary target for
PRRSV infection (Duan et al., 1997). Additionally, dendritic cells were proved to be permissive
to PRRSV infection (Loving et al., 2007). In vitro, the African green monkey kidney cell line
MA-104 and its derivate cell lines, MARC-145 and CL-2621, are reported to support PRRSV
infection and replication. In addition, some recombinant cell lines, such as CHO-K1, BHK-21
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and porcine kidney cell-15 (PK-15), are generated from originally non-permissive cells and
turned susceptible to PRRSV infection upon expression of recombinant receptor proteins (Shi et
al., 2015a).
The receptor-mediated PRRSV entry has been well documented with various receptors
reported involved in this process (Delputte et al., 2005; Shi et al., 2015a; Van Breedam et al.,
2010). Heparan sulphate was identified as one PRRSV attachment factor that concentrate virions
on the cell surface, but it is not sufficient to render cells permissive to PRRSV since many nonpermissive cells possess heparan sulphate (Delputte et al., 2005). After early attachment of
virions to heparan sulphate, another attachment receptor, sialoadhesin, was reported to mediate
more stable interaction with PRRSV. Then the virus internalizes the host cells via a process of
clathrin-mediated endocytosis (Delputte et al., 2005; Vanderheijden et al., 2003). However,
sialoadhesin is not essential for PRRSV infection either. In an in vitro study, PRRSV was able to
enter naturally non-permissive PK-15 cells transfected with sialoadhesin, but not capable of
reproductive replication in the transfected cells (Prather et al., 2013). After internalization, the
viral genome is then released into early endosomes (pH = 6.0 to 6.5) following endosome
acidification and viral colonization with scavenger receptor CD163 (Van Gorp et al., 2009).
CD163 plays a pivotal role in viral uncoating and genome release of PRRSV, and is postulated
the only known indispensable receptor for PRRSV infection so far. Evidence supporting its
indispensability for PRRSV infection includes an in vitro study reporting that overexpression of
CD163 alone in BHK-21 (an originally PRRSV non-permissive cell) confers the cells
susceptibility to PRRSV infection (Guo et al., 2014). In addition, in vivo experiments revealed
that CD163 knock-out pigs are resistant to PRRSV infection (Burkard et al., 2017; Whitworth et

9

al., 2015). Therefore, CD163 was identified as a key factor in the initiation of PRRSV infection
and may be targeted to control PRRSV infection.

1.6

Scavenger receptor CD163 in PRRSV infection and its regulation

1.6.1 CD163 in PRRSV infection
CD163 is a type I transmembrane glycoprotein which belongs to the scavenger receptor
cysteine- rich (SRCR) family and is mainly expressed on cells of the monocyte/macrophage
lineage (Van Breedam et al., 2010). Extracellularly, it is made up of nine SRCR domains with
SRCR domain 6 (SRCR6) and SRCR7 separated by a 35-amino-acid proline-serine-threonine
(PST)-rich region and a signal peptide following SRCR9 (Van Breedam et al., 2010; Van Gorp
et al., 2010) (Figure 1.2). In a previous study, a set of chimeric mutants of CD163 were
generated by swapping SRCR domains with corresponding regions of CD163-L1, a paralogue of
human CD163 that does not promote PRRSV infection (Van Gorp et al., 2010). Then PRRSVnon-permissive HEK293T cells were transfected with different chimeric mutants and the
potential of the different mutants to sustain PRRSV infection was evaluated. The SRCR5 of
CD163 was identified to have a leading role in PRRSV infection. Another study identified
glycoproteins of PRRSV that were responsible for mediating interaction with CD163 (Das et al.,
2010). CD163 receptor as well as each of the glycoproteins of PRRSV were sub-cloned into
expression vectors and these constructs were transfected into BHK-21 cells. The interactions of
the proteins with each other in the transfected cells were examined using coimmunoprecipitation.
The results suggested that PRRSV glycoproteins GP2a and GP4 served as the viral attachment
proteins that interacted with CD163 for virus entry into susceptible host cells (Das et al., 2010)
(Figure 1.3).
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1.6.2 Regulation of CD163 expression
The regulatory mechanism for CD163 expression has been extensively studied in humans
due to its anti-inflammatory roles. CD163 is exclusively expressed in monocytes/macrophages
(Buechler et al., 2000). Anti-inflammatory cytokine Interleukin 6 (IL-6) and IL-10 substantially
stimulate, whereas proinflammatory cytokines interferon-γ (IFN-γ) and tumor necrosis factor-α
(TNF-α) strongly inhibit CD163 transcription and protein expression (Buechler et al., 2000;
Sulahian et al., 2000). Among these cytokines, IL-10 is responsible for the regulatory T cellinduced expression of CD163 in monocytes/macrophages, and the upregulation of CD163
induced by the activation of Toll like receptor (TLR) 2 or TLR5 agonists (Tiemessen et al., 2007;
Weaver et al., 2007), or upon the stimulation with lipopolysaccharide (LPS) or hemoglobinhaptoglobin (HbHp) complex (Boyle et al., 2009; Sulahian et al., 2004). IFN-γ inhibits CD163
expression through regulating IL-10. IFN-γ and IL-10 mutually suppress the expression of each
other in monocytes (Donnelly et al., 1995), and the inhibition of CD163 expression by IFN-γ can
be rescued by exposure to IL-10 in peripheral blood mononuclear cells (PBMCs) (Weaver et al.,
2007). Additionally, IL-10 inhibits the expression of TNF-α (another CD163 inhibitor) induced
by IFN-γ or LPS in both PBMCs and alveolar macrophages (Chomarat et al., 1993; Donnelly et
al., 1995). Therefore, IL-10 plays a central part in modulating CD163 transcription in humans.
In human macrophages, IL-10 stimulation activates Janus Kinase (JAK), which
specifically activates signal transducer and activator of transcription 3 (STAT3) (Carey et al.,
2012; Murray, 2007). The activated STAT3 dimerizes and translocates into the cell nucleus for
transcriptional regulation (Carey et al., 2012; Murray, 2007). Inhibition of STAT3 significantly
downregulates the transcription of both IL-10 and CD163 (Hasita et al., 2010; Nakamura et al.,
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2015), identifying the IL-10- stimulated signaling pathway as a valuable target for inhibiting
CD163 expression.
The regulation of CD163 expression in pigs has yet to be elucidated, although porcine
CD163 shares conserved amino acid sequence and functional domains to its counterparts in
human, primate, and rodent (Perez et al., 2008), and is abundantly expressed in pig macrophages
(Sánchez et al., 1999). The regulatory sequence that mediates CD163 gene expression in pigs is
still unknown. However, similar to humans, IL-10 stimulates CD163 expression in pig
monocytes at the protein level (Perez et al., 2008; Sánchez et al., 1999). Furthermore, the IL-10induced increase of CD163 protein expression leads to greater susceptibility of pig macrophages
to PRRSV infection (Patton et al., 2009). These data support that the IL-10- stimulated signaling
pathway is a potential target for the prevention PRRSV infection by inhibiting CD163
expression. However, whether porcine CD163 transcription is regulated by IL- 10-stimulated
signaling pathway similarly to humans is unclear. In addition, whether we can minimize PRRSV
susceptibility of porcine alveolar macrophages (PAMs), the primary PRRSV target in pigs by
modulating the signaling pathway has not been explored.

1.7

Viral replication cycle
As described in section 1.5 Viral Infectivity, PRRSV internalizes the host cells via a

process of clathrin-mediated endocytosis and has its genome released to the host cell cytoplasm
following endosome acidification and viral colonization with scavenger receptor CD163. CD163
mediates uncoating and release of the viral genome, which is followed by initiation of translation
and transcription processes required for the formation of new virions. The ORF1a/b on the first
three-fourths of the genome yield replicase polyproteins pp1a, pp1a-nsp2N, pp1a-nsp2TF, and
pp1ab through two programmed ribosomal frame shift sites (Fang et al., 2012) (Figure 1.4).
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These polyproteins are cleaved by viral internal proteinases papain-like cysteine proteinases
(PLP) 1α, PLP1β and PLP2, and the main serine proteinase to generate at least 14 nonstructural
proteins (Snijder et al., 2013). These nonstructural proteins are then assembled into a replication
and transcription complex (RTC) following rearrangement of host membranes (Yuan et al.,
2004). First, the RTC engages in the synthesis of minus-strand full-length genome and a set of
nested subgenomic RNAs (sgRNAs) (Pasternak et al., 2004) (Figure 1.4). Subsequently, minusstrand genome and sgRNAs serve as templates to synthesize plus-strand genome and sgRNAs.
The set of nested sgRNAs (+) yield corresponding structural proteins as indicated in Figure 1.4
(Kappes and Faaberg, 2015). The generated genome RNA is assembled with these structural
proteins in a highly ordered process, which include formation of heterodimer composed of GP5
and M, synthesis of a hetero-trimer that facilitates viral entry consisting of minor glycoproteins
GP2a, GP3 and GP4 (Mardassi et al., 1996; Wissink et al., 2005), and enclosure of genome RNA
by a core capsid formed by homo-oligomerization of N protein (Wootton and Yoo, 2003; Yoo et
al., 2003). After the assembly, the virion becomes enveloped by budding from smooth
intracellular membranes (Wissink et al., 2005). Ultimately, the new virions accumulate in
intracellular vesicle, which are subsequently delivered to the plasma membrane before shed from
the cells via an exocytosis process (Wissink et al., 2005).

1.8

Innate and adaptive immunity against PRRSV

1.8.1 Type I interferon response
The most effective innate anti-viral immune response is the production of type I
interferons (IFNs) IFN-α and IFN-β by infected cells, of which the autocrine and paracrine
actions instigate the comprehensive host immune response to protect the host cells against viral
infection in the early stages. Macrophages and dendritic cells are the most potent cells of

13

producing type I IFN, notably a subset of dendritic cells, namely, plasmacytoid dendritic cells
(pDCs). Signaling pathways for type I IFN production will be reviewed below (Figure 1.5).
Toll-like receptors (TLRs) have been well documented in their functions of mediating
type I IFN production. Among them, endosome-based TLRs 3, 7, 8, and 9 have been reported to
contribute extensively to the control of virus infection (Baccala et al., 2007). TLR3 is present in
intracellular endosomes of most cell types and it recognizes pathogen-associated molecule
patterns (PAMPs) poly(I:C) and double stranded RNA (dsRNA) (Karikó et al., 2004; Okahira et
al., 2005). TLR7 in human is abundantly expressed in pDCs while TLR8 is primarily present in
monocytes and they both recognize single-stranded RNA (ssRNA) as PAMPs (Gantier and
Williams, 2007). TLR9 senses unmethylated CpG DNA in the genome in DNA viruses (Vollmer
et al., 2004). Binding with the PAMPs leads to the dimerization of corresponding receptors and
recruitment of Toll/IL-1R domain-containing adaptor inducing IFN-β (TRIF) by TLR3
(Vercammen et al., 2008) or MyD88 by TLRs 7/8/9 (O'Neill and Bowie, 2007). The stimulation
of TRIF or MyD88 leads to the assembly of signaling complexes and initiation of signaling
cascades resulting in the phosphorylation and activation of Activating Protein 1 (AP-1), NF-κB,
interferon regulatory factor 3 (IRF3), and IRF7 (Honda et al., 2006; Vercammen et al., 2008).
After the activation, these transcription factors translocate to the cell nucleus and bind with cotranscription factors CREB-binding protein (CBP) to form an IFN enhanceosome to induce the
transcription of IFN-α and IFN-β.
Another signaling mediating type I IFN production is Retinoic acid inducible gene I and
melanoma differentiation associated gene-5 (RIG-I/MDA5) pathway (Figure 1.5). RIG-I and
MDA-5 are both DExD/H box RNA helicases with ATPase activity, which possess two Nterminal caspase recruitment domains (CARDs). RIG-I recognizes short dsRNA ligands
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(<300 bp) with 5′-triphosphate caps (Hornung et al., 2006) whereas MDA5 recognizes long
double stranded genomic RNA and replication intermediates (>1,000 bp) with no end specificity
(Pichlmair et al., 2006). The PAMPs binding induces conformational changes and oligomeric
CARD assemblies between RIG-I and MDA5 which nucleate the polymer formation of the
signaling adaptor IFN-β promoter stimulator-1 (IPS-1), another CARD-containing protein on the
mitochondrial and peroxisomal membranes (Berke and Modis, 2012). Subsequently, the IPS-1
polymers stimulate signaling pathways that result in the activation of IRF3, IRF7, and NF-κB
through different adaptors and kinases (Hou et al., 2011). The IPS-1 also cascades its signal to
MAP kinase which is involved in the activation of AP-1 (Liu et al., 2014). The activated IRF3,
IRF7, NF-κB, and AP-1 are translocated into the nucleus, and recruit co-transcription factors,
such as CBP to form IFN enhanceosome to induce the transcription of IFN-α and IFN-β (Honda
et al., 2006). Additionally, another mediator, LGP2 has similar helicase and C-terminal domain
as RIG-I and MDA5 but lacks the tandem CARDs (Barral et al., 2009). LGP2 downregulates
signaling by RIG-I attributed to its ability of competitively recognizing the same PAMPs as RIG1 (Rothenfusser et al., 2005; Yoneyama et al., 2005). In contrast, LGP2 stimulates MDA5
signaling (Yoneyama et al., 2005). Thus, LGP2 could control the balance between RIG-I and
MDA5 responses during viral infection.
Once IFN-α and IFN-β are synthesized through either TLR signaling or RIG-I/MDA5
pathway, they are secreted extracellularly and bind to IFN receptors on itself (autocrine) or
neighboring cells (paracrine). The binding initiates JAK-STAT signaling pathway (Figure 1.5)
that upregulates over 300 IFN-stimulated genes (ISGs) which later result in the establishment of
antiviral state in uninfected cells. The binding to receptor induces conformational changes in the
receptors which activate Jak1 and Tyk2 pre-associated on the receptors. The activated Jak1 and
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Tyk2 phosphorylate the signal transducers and activators of STAT1 and STAT2 followed by the
STAT1-STAT2 dimerization in the cytosol. The heterodimer recruits IRF9 and form the
transcription factor complex namely Interferon-stimulated gene factor 3 (ISGF3). ISGF3 then
translocates into the nucleus and binds to a consensus DNA sequence of TTTCNNTTTC known
as IFN-I-stimulated response element (ISRE) leading to the activation of transcription of over
300 ISGs (Ivashkiv and Donlin, 2014). However, a relatively small number of these genes confer
antiviral state to uninfected cells by cytoskeletal remodeling for apoptosis, regulation of posttranscriptional events, and post-translational modifications. Many other ISGs serve as patternrecognition receptors (PRRs) to recognize viral molecules or as transcription factors that
facilitate IFN production and preventing virus infection (Sadler and Williams, 2008). Among all
the ISGs, 2', 5'-oligoadenylate synthetase 1 (OAS1), RIG-I, RNA activated Protein Kinase
(PKR), myxovirus resistance (MxA), and ISG15 are the most extensively studied, and function
as antiviral effectors (Sun et al., 2012).
1.8.2 Innate immune responses to PRRSV infection
The innate immunity is the first line of host defense against viral infections. It includes
physical barriers, such as skin and mucous membrane; chemical barrier, like pH, lipids and
enzymes; and immune cells, such as dendritic cells, macrophages, neutrophils, mast cells, and
natural killer (NK) cells. The most effective innate anti-viral immune response is type I IFN
production by the virus-infected cells. PRRSV has been reported to modulate host innate
immunity, and in turn adaptive immunity leading to chronic persistent infection as previous
studies have shown that virus can be detectable from secondary lymphoid organs such as tonsils
and lymph nodes months after initial infection (Allende et al., 2000; Loving et al., 2015; Lunney
et al., 2016). Unlike other swine respiratory viruses that are capable of inducing considerable
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IFN-α response, e.g. swine influenza virus and porcine respiratory coronavirus, PRRSV
stimulates moderate to negligible IFN-α production in the respiratory tract. Suppression of Type
I IFNs in pigs infected with HP-PRRSV (Xiao et al., 2010) or European genotype of PRRSV
(Ait-Ali et al., 2011) has been validated using microarray analysis, indicating that PRRSV is able
to manipulate IFN signaling pathways during infection.
TLR3, TLR7, and TLR8 have been identified important for type I IFNs production and
thus innate antiviral activity against PRRSV infection. Porcine bone marrow hematopoietic cellderived immature dendritic cells (imDCs) were exposed to PRRSV in a previous study which
showed such exposure inhibited TLR3, TLR7, and TLR8 expression at 6 h post infection (hpi) in
the imDCs, and that TLR3 and TLR8 levels returned to basal levels by 24 hpi whereas TLR7
expression decreased continuously through 24 h of infection (Chaung et al., 2010), suggesting
that PRRSV may suppress type I IFNs production through TLR signaling. In contrast, TLR3
level in PRRSV-infected cells was significantly downregulated by poly(I:C) or LPS in another
study, which facilitated PRRSV replication (Miller et al., 2009).
A number of PRRSV Nsp’s have been reported to suppress type I IFNs production by
targeting IFN enhanceosome through IRF-mediated RIG-I/MDA5 pathways. Nsp 1 possesses the
most potent ability to suppress the IFN-β activity partly due to the degradation of CBP in the
nucleus. Consequently, the enhanceosome formation is disrupted and then the IFN gene
expression is blocked (Kim et al., 2010). Nsp1β is able to suppress type I IFNs by inhibiting
phosphorylation and nuclear translocation of IRF3 (Kim et al., 2010). Nsp2 is known to
downregulate type I IFNs production due to its poliovirus 3C-like cysteine protease (CP) and
deconjugation activities associated with inhibiting IRF3 phosphorylation and nuclear
translocation, and with mediating ISGs and NF-κB signaling, respectively (Li et al., 2010).
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Nsp11 blocks the phosphorylation of both IκB and IRF3 which leads to the suppression of the
nuclear translocation of NF-κB and IRF3 and to the consequent inhibition of IFN production.
The inhibition of NF-κB and IRF3 is likely caused by the degradation of the upstream IPS-1 by
Nsp11 (Nedialkova et al., 2009). Another pathway involving a protective response of the host to
viruses and modulated by PRRSV is NF-κB signaling. The PRRSV N protein appears to induce
NF-κB activation in a dose-dependent manner and the activation may be linked to the N protein
nuclear localization and N-N homo-dimerization (Sun et al., 2012). In contrast, Nsp1α was found
to be able to inhibit the NF-κB activation by inhibiting the phosphorylation of the upstream IκBα
and then blocking the NF-κB nuclear translocation (Song et al., 2010). Nsp2 has also been
reported to suppress the NF-κB activation though the mechanism is obscure (Li et al., 2010).
PRRSV not only inhibit type I IFN production but also deter the host cell from
establishing antiviral state by suppressing the IFN-inducible signaling pathways, primarily JAKSTAT signaling (Patel et al., 2010). PRRSV inhibits JAK-STAT signaling by blocking ISGF3
translocation into nucleus (Patel et al., 2010). PRRSV also induces STAT2 degradation and
shortens STAT2 half-life significantly by nsp11 interaction with STAT2 to inhibit JAK-STAT
signaling (Yang et al., 2019). It was found that PRRSV significantly inhibits ISGs expression
both in MARC145 cells and PAMs as indicated by the decreased ISG15, ISG56 transcription and
CCL2, MX1, OAS2 mRNA in the PRRSV-infected cells, respectively (Patel et al., 2010).
Additionally, PRRSV infection may undermine activation of the host innate system
through dysregulation of NK cells. NK cells are the innate lymphocyte subset involved in the
nonspecific elimination of any virus-infected cells from the host. Following infection with
PRRSV, NK cell frequency decreases but returns to normal levels a few weeks after PRRSV
infection (Dwivedi et al., 2011b). However, independent of the fluctuation in NK cell number by
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PRRSV infection, suppression of NK cell cytotoxic activity is observed as early as two days post
initial infection and continues for three to four weeks (Dwivedi et al., 2011a; Renukaradhya et
al., 2010). The modulation of these NK cell properties during PRRSV infection is coordinated by
multiple cytokines, such as IFNα, IFNβ, IL-12, and IL-15, and the debilitated basal NK cell
cytotoxic activity by viral infection is mediated through the STAT1 pathway (Lee et al., 2000).
1.8.3 Adaptive immune responses to PRRSV infection
Though PRRSV evades the host innate immune response to avoid rapid clearance from
the host, the impaired host innate immunity against viral infection may cascade its effect to
adaptive immune response of the host during PRRSV infection, contributing to PRRSV
persistence in the host. One key feature of the dysregulated adaptive immune responses to
PRRSV infection is delayed secretion of neutralizing antibodies (NAbs). NAbs are not usually
detected prior to 4 weeks after initial challenge (Yoo et al., 2010). Though PRRSV infection
stimulates an antibody response by as early as 7 to 9 days post infection, no evidence shows that
early antibodies can provide sterilizing immunity against PRRSV challenge to the pig (Lopez et
al., 2007; Lopez and Osorio, 2004). These earliest and non-neutralizing antibodies are directed
against the 15 kDa N protein, the 19 kDa M protein and then the 26 kDa GP5 envelope
glycoprotein chronologically (Loemba et al., 1996). Interestingly, epitope mapping identifies a
range of non-neutralizing epitopes located in Nsp2, suggesting that this major nonstructural
protein serves an immunodominant role (de Lima et al., 2006; Oleksiewicz et al., 2001). Reports
in regard to the role of NAbs against PRRSV infection have been confounding and sometimes
paradoxical. For examples, some studies indicate that viremia and viral replication can persist
with circulating NAbs, and in other cases, viremia vanishes from the host before NAbs appears
(Mateu and Diaz, 2008; Nelson et al., 1994; Vezina et al., 1996). PRRSV persists in lymphoid
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tissues, such as tonsils and lymph nodes in presence of high-titers of circulating homologous
PRRSV NAbs (Murtaugh et al., 2002). These together can be interpreted as the idea that PRRSV
NAbs are not directly correlated with PRRSV clearance. In contrast, serum transfer experiments
show that high-titered NAbs can transfer passive protection and prevent transplacental PRRSV
infection of piglets and confer sterilizing immunity against PRRSV infection on both the sow
and her offspring in utero (Lopez et al., 2007).
Glycan shielding effects of N-linked glycosylation in glycoproteins have been postulated
to be a primary mechanism for delayed NAbs (Ansari et al., 2006). It has also been reported that
an upstream decoy epitope lures the immune response away from more protective neutralizing
epitope in GP5 (Ostrowski et al., 2002). Another factor that may contribute to delayed secretion
of NAbs is a known phenomenon as antibody-dependent enhancement in which infection and
replication of PRRSV are enhanced in the presence of specific antibody in vivo and in vitro
(Cancel-Tirado et al., 2004). In addition, PRRSV dysregulates innate immunity and causes
abnormal B cell repertoire development, particularly lymphopenia and thymic atrophy, which
may hinder virus clearance by NAbs (Butler et al., 2014).
As described above, PRRSV infection is able to dysregulate IFN-α response. The
autocrine IFN-α may induce pDCs to express co-stimulatory molecules that facilitate the
differentiation of naïve T cells into IFN-γ-producing cells (Honda et al., 2003). Therefore,
PRRSV can also affect adaptive immune response of the host by the cascading effects of
dysregulated innate immunity by PRRSV challenge. The lack of efficient stimulation of IFN-α
secretion in host cells by PRRSV exposure would be expected to have a major impact on the
cell-mediated immunity of the host, for IFN-α stimulates IFN-γ gene expression, and thus control
the dominant pathway that promotes T cell-mediated IFN-γ responses and robust antiviral
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immune defenses (Levy et al., 2003). Apart from phenotypic changes of T lymphocytes by
PRRSV infection, this viral challenge can also induce a reduction in circulating lymphocyte early
after infection in young pigs, constituting another potential mechanism that PRRSV
compromises host’s adaptive immune responses against the virus (Sinkora et al., 2014).

1.9

Antiviral strategies against PRRSV infection
Vaccination for food animals is a common approach to combat infectious disease.

Currently, commercial modified live vaccines (MLV) has been developed against both PRRSV1 and PRRSV-2 strains, and licensed in various regions depending on the circulating strains (Du
et al., 2017). However, unlike MLVs against EAV that provide effective protection to the horses,
efforts to control PRRSV infection using MLVs fail primarily because MLVs based on a single
PRRSV strain provide poor cross-protection against heterologous strains (Zhou et al., 2012).
Various potential antiviral strategies other than conventional MLVs have emerged in recent
years. These strategies suppressed PRRSV infection at different steps of the PRRSV replication
cycle, or target some antiviral signaling to boost host immunity against PRRSV (Zhou et al.,
2012).
The two PRRSV receptors, sialoadhesin and CD163 mediate virion internalization to the
host cells and viral uncoating, respectively. Soluble form of sialoadhesin and CD163 from
transduced 3D4/21 or PK-15 cells are able to capture PRRSV virion and inhibit PRRSV
infection of PAMs in vitro, and the anti-PRRSV activity is even more striking when the PRRSVinfected PAMs are co-treated with secretory sialoadhesin and CD163 (Chen et al., 2014). A
mouse (Mus musculus) monoclonal anti-idiotypic antibody (Mab2-5G2) hampers interaction of
PRRSV GP5 and MYH9 C-terminal domain to block PRRSV entry (Gao et al., 2016; Zhou et
al., 2008).
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RNA interference techniques, either small interfering RNAs (siRNAs) or short-hairpin
RNAs (shRNAs), targeting nonstructural protein (Nsp) 1α (Shi et al., 2015b) and Nsp9 (Xie et
al., 2014), and the genes encoding the nucleoprotein (Yang et al., 2014), and ORF1 region of
PRRSV (Li et al., 2007) have been reported to block PRRSV infection in vitro. Nanobodies
targeting Nsp4 and Nsp9 have been screened for anti-PRRSV efficacy, and these nanobodies
were shown to inhibit PRRSV replication by interfering PRRSV replication and transcription
complex (RTC) assembly (Liu et al., 2016; Liu et al., 2015).
Some crude traditional Chinese medicine (TCM) extracts, including Tanshinone IIA from
root of Salvia miltiorrhiza (Sun et al., 2014), Epigallocatechin gallate (Zhao et al., 2014) and tea
seed saponins (Li et al., 2015) from tea, and flavaspidic acid AB from Dryopteris crassirhizoma
(Yang et al., 2013), have been shown to inhibit PRRSV replication in vitro. However, all of these
studies only tested anti-PRRSV activity of crude extracts or agents but not specific agents in
vitro and did not characterize efficacy in vivo. Additionally, some of them seem to inhibit
replication of various viruses and the underlying mechanisms for their antiviral ability are still
elusive. Therefore, TCM extracts are far from being ready for practical use in anti-PRRSV
therapy.
As for agents stimulating antiviral signaling against PRRSV, several Toll-like receptor
(TLR) ligands, including poly (I:C), SZU-101, and CL907, which are recognized by TLR3,
TLR7, and TLR7/8, respectively, are shown to inhibit PRRSV replication in vitro by activating
the innate immune response (Du et al., 2016; Hu et al., 2016; Miller et al., 2009; Sang et al.,
2008; Zhang et al., 2013). In addition, recombinant porcine IFN-β and IFN-γ are able to inhibit
PRRSV replication in vitro, showing some vaccine adjuvant potential (Bautista and Molitor,
1999; Overend et al., 2007). Pigs that were inoculated with recombinant adenovirus for IFN-α
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expression one day prior to PRRSV challenge show delayed viremia and antibody response and
alleviated lung lesion (Brockmeier et al., 2009). In an in vivo study, recombinant pig IL-12 was
reported to boost humoral and cell-mediated anti-PRRS immunity in swine when used as an
adjuvant with an inactivated vaccine (Wee et al., 2001).

1.10 Rational and hypotheses of this research
Either MLVs and inactivated vaccines provide poor cross-protection against heterologous
PRRSV strains. In addition, despite tremendous efforts in investigating alternative methods as
described above, efficient control of PRRS is still lacking. Though the indispensability of CD163
receptor for PRRSV infection in pigs has been well documented, few studies have targeted
porcine CD163 using small molecules to inhibit PRRSV infection either in vitro or in vivo. In
this research, 2 hypotheses were raised: 1) We propose that the downregulated porcine CD163
expression by small molecules will protect PAMs against heterologous PRRSV strains in vitro.
2) We further propose that small molecules that disrupt the CD163-PRRSV interaction will
provide PAMs with cross-protection against heterologous PRRSV strains in vitro. These 2
hypotheses were addressed in the following 2 research projects, respectively.
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Figure 1. 1: Genome and virion structures of PRRSV. (A) The two ORFs on the 5’ end of the
genome encode four large nonstructural polyproteins, pp1a, pp1a-nsp2N, pp1a-nsp2TF, and pp1ab
that are subsequently cleaved into at least 16 nonstructural proteins. The remaining ORFs of the
genome on the 3’ end encode structural proteins associated with viral envelope and RNA
packaging. (B) A PRRSV mature virion consists of single stranded genome enclosed in
nucleocapsid proteins which is further wrapped up in a lipid bilayer envelope with multiple viral
glycoproteins. The figure is from (Montaner-Tarbes et al., 2019).
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Figure 1. 2: Schematic structure of scavenger receptor CD163. From N terminus to C terminus,
the receptor is made up nine SRCR domains with SRCR domain 6 (SRCR6) and SRCR7 separated
by a 35-amino-acid proline-serine-threonine (PST)-rich region and with SRCR9 followed by a
signal peptide. The figure is modified from (Van Breedam et al., 2010).
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Figure 1. 3: A preliminary model of the PRRSV envelope protein complex and its interaction
with CD163 on the host cell plasma membrane. The pearl-on-a-string structure on the
extracellular region of the host cell represent the nine SRCR domains making up the extracellular
scavenger receptor CD163. The two glycoproteins on the PRRSV envelope, namely GP2a and
GP4, collaborate to mediates PRRSV interaction with the CD163 at the fifth SRCR domain
(SRCR5) for virus entry. The figure is from (Das et al., 2010).
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Figure 1. 4: PRRSV genome, transcription and translation. PRRSV replication is
accomplished by a range of genetic and protein regulatory mechanisms. The two ORFs making up
about three fourth of PRRSV genome encode 4 large polyproteins, namely pp1a, pp1a-nsp2N,
pp1a-nsp2TF, and pp1ab through two documented programmed ribosomal frame shift sites (●).
Subsequently, the polyproteins are cleaved into at least 14 nonstructural proteins which are then
assembled into a replication and transcription complex (RTC). The RTC engaged in the synthesis
of minus-strand full-length genome and a set of nested subgenomic RNAs (sgRNAs) before they
serve as template to produce positive-strand genome and sgRNAs which encode glycoproteins on
the envelope and nucleocapsid. The figure is from (Kappes and Faaberg, 2015).
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2.1. Toll-Like Receptor (TLR) Signaling
Toll-like receptors (TLRs) have been investigated extensively in the past few years and a
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proteins recognizing different pathogen-associated molecule patterns (PAMPs). The key signaling
domain unique to the TLR system is the toll/interleukin (IL)-1 receptor (TIR) domain located in the
cytosolic face of each TLR and also in the adapters [26]. Once engaged to TLRs, PAMPs recruit
different kinases through different adaptors by the TIR domain and thus trigger different signaling
pathways, leading to the expression of specific genes that are involved in the removal of invading
viruses. Ten TLRs have so far been identified for humans and 11 TLRs for mice [27]. Of these, TLRs
3, 7, 8, and 9 are discussed in this review since they contribute the most to the control of virus
infection [28].
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Abstract Porcine reproductive and respiratory syndrome (PRRS), caused by PRRS virus
(PRRSV) infection, causes enormous financial losses to the global swine industry. Currently
there are no effective treatments to prevent PRRSV infection in pigs. Here we report that the
natural compound cryptotanshinone (Cpt) is able to effectively inhibit PRRSV infection by
heterologous PRRSV strains in porcine alveolar macrophages (PAMs) in vivo, the primary cell
target of PRRSV infection. Mechanistically, Cpt inhibits the activation of signal transducer and
activator of transcription 3 (STAT3), and blocks the interleukin 10 (IL-10) stimulated, as well as
the basal level CD163 expression in PAMs. Cpt- treatment of PAMs is effective when
administered either before or after PRRSV infection, or with the combined pre- and post-PRRSV
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infection treatment resulting in significant, dose-dependent inhibition of PRRSV infection. Our
study identified a new approach to potentially preventing/treating PRRSV infection by using
natural compounds.
Keywords PRRSV, IL-10, STAT3, CD163, Cryptotanshinone, PAM

2.1

Introduction
Porcine reproductive and respiratory syndrome (PRRS) leads to an annual loss of $664

million to the United States pork industry, and is one of the most economically significant
diseases for swine industry worldwide (Holtkamp et al., 2013). The causative agent of the
disease is porcine reproductive and respiratory syndrome virus (PRRSV), an enveloped, positivesense, single-stranded RNA virus, belonging to the Arterivirus genus within the family
Arteriviridae and order Nidovirales (Benfield et al., 1992; Cavanagh, 1997). PRRSV is divided
into two genetically distinct genotypes, type I (European genotype) and type II (North American
genotype). PRRS leads to severe reproductive disorders in sows and respiratory diseases mostly
in piglets (Music and Gagnon, 2010). These syndromes are frequently accompanied by
secondary infections with even more severe clinical manifestations and mortality (Zimmerman et
al., 1997). However, due to the high genetic, antigenic, and pathogenic heterogeneities among
various PRRSV strains, vaccines providing cross-strain protection against PRRSV are lacking
(Meng, 2000; Murtaugh et al., 2010). Alternative approaches to combatting the PRRS panzootic
are worthy of studying.
PRRSV has a narrow cell tropism in pigs, preferentially targets and replicates in welldifferentiated cells of monocyte/macrophage lineage (Duan et al., 1997; Music and Gagnon,
2010; Rossow, 1998; Teifke et al., 2001; Thanawongnuwech et al., 1997). Productive viral
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infection occurs principally in porcine alveolar macrophages (PAMs) residing in the lung
(Murtaugh et al., 2002). In vitro, the African green monkey kidney cell line MA-104 and its
derivates, MARC-145 and CL-2621, are shown to support PRRSV infection and replication
among many tested cell lines. CD163, a cell membrane scavenger receptor, is the key receptor
for PRRSV infection in pigs. Genetic knockout studies revealed that deletion of CD163, but not
another receptor sialoadhesin, produced PRRSV- resistant pigs (Prather et al., 2013; Whitworth
et al., 2015). PRRSV directly interacts with CD163 via its minor glycoproteins GP2a and GP4
(Das et al., 2010), and CD163 is reported to mediate the uncoating and genome release of the
virions for productive infection after virion internalization (Van Gorp et al., 2008, 2009;
Vanderheijden et al., 2003). However, cellular mechanisms that regulate pig CD163 expression
are still obscure.
In human cells of the monocyte/macrophage lineage, cytokines interleukin 6 (IL-6) and
IL-10 substantially stimulate CD163 transcription and expression (Buechler et al., 2000; Högger
et al., 1998; Sulahian et al., 2000). IL-6 or IL-10 stimulation activates Janus kinase (JAK), which
specifically activates the transcription factor signal transducer and activator of transcription 3
(STAT3) (Carey et al., 2012; Murray, 2007). Inhibiting STAT3 significantly downregulates the
transcription of both IL-10 and CD163 (Hasita et al., 2010; Nakamura et al., 2015), identifying
that IL-10- stimulated signaling pathway as a valuable target to inhibit the expression of CD163.
However, little is known about the regulation of CD163 expression in pigs, although porcine
CD163 shares conserved amino acid sequence and functional domains with its human, primate,
and rodent counterparts (Perez et al., 2008), and is highly expressed in macrophages (Sánchez et
al., 1999). It was reported that in pig macrophages, IL-10−induced increase of CD163 protein
expression which leads to a greater susceptibility to PRRSV infection (Patton et al., 2009). These

44

data support that the IL-10−stimulated signaling pathway is a potential target for the prevention
of PRRSV infection. However, whether porcine CD163 is transcriptionally regulated by IL-10
similarly as in humans is unclear. Also, whether we can minimize PRRSV susceptibility of
PAMs, the primary PRRSV target in pigs, by modulating the activities of CD163 expressionregulating pathways has not been explored.
Here we report that in primary PAMs, inhibiting IL-10 controls STAT3 activity and
CD163 expression at the transcriptional and translational levels. We further discovered that
Cryptotanshinone (Cpt), a selective STAT3 inhibitor and natural compound derived from the
herb Salvia miltiorrhiza (Danshen) (Chen et al., 2014; Shin et al., 2009), exhibits significant
inhibitory effect to the infection of PAM cells by type I and type II PRRSV in PAMs.

2.2

Materials and Methods
Chemicals, Cells, and Viruses. STAT3 inhibitors Stattic, 5,15-DPP (Stat3 Inhibitor

VIII) and Cpt were purchased from Abcam (Cambridge, MA, USA). Porcine IL-10 was from
R&D Systems (Minneapolis, MN). PAMs were harvested from healthy 4–6-month old castrated
male Landrace/Yorkshire cross pigs based on a protocol approved by the institutional animal
care and use committee (IACUC) at the University of Connecticut. Briefly, lungs were removed
from euthanized pigs during necropsy and transferred on ice to a Class II Biosafety cabinet. A
bronchoalveolar lavage was then performed by injection of 200 mL warm sterile PBS containing
200 U/mL penicillin and 200 µg/mL streptomycin through trachea into major bronchi of both
sides of the lungs. Lungs were massaged and bronchoalveolar lavage fluid was collected. The
fluid was centrifuged at 400 g for 15 min to collect PAMs. The PAMs were washed twice,
counted and frozen in 90% fetal bovine serum (FBS) (Rocky Mountain Biologicals, Missoula,
MT) and 10% dimethyl sulfoxide (DMSO) (Sigma- Aldrich, St. Louis, MO) at -80 ℃ overnight
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before transferred to liquid nitrogen. PAMs were cultivated in RPMI-1640 (Life Technologies,
Calsbad, CA) supplemented with 10% FBS (Rocky Mountain Biologicals), 2 mM Glutamax
(Invitrogen, Carlsbad, CA), 0.1 mM MEM Non-Essential Amino Acids, 1mM sodium pyruvate,
100 U/mL penicillin and 100 µg/mL streptomycin, and 0.5 µg/mL Amphotericin B
(ThermoFisher Scientific, Grand Island, NY). Type I PRRSV strain Lelystad (LY), and type II
PRRSV strains VR- 2332 and SDSU73 used for infection assays were propagated and titrated
using MARC145 cells as described previously (He et al., 2011; Overend et al., 2007).
Determination of Cytotoxicity of STAT3 inhibitors. PAMs (1×107 cells) were seeded
into a 24-well plate. After overnight incubation, three STAT3 inhibitors were diluted with
complete medium to different concentrations (0 - 20 µM), and 500 µl of each concentration was
added to PAMs. Cells were incubated for 24 h, then 50 µl of the 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) labeling reagent (In Vitro Toxicology Assay Kit, MTT
based, Sigma- Aldrich) were added to each well for 4 h, followed by 500 µl of the solubilization
solution into each well to fully dissolve the formazan crystal by overnight incubation based on
manufacture’s instruction. The absorbance of samples was measured using a spectrophotometry
microplate reader at 600 nm. PAMs treated with DMSO were served as controls.
Quantitative Reverse Transcription – PCR (qRT-PCR). Total RNAs were isolated
from PAMs using RNeasy Mini Kit (Qiagen, Germantown, MD) according to the manufacturer’s
instruction. RNA concentrations were measured using a Nanodrop spectrophotometer
(ThermoFisher Scientific). Specific real-time qPCR primers for STAT3, SOCS3, CD163,
GAPDH, and the ORF7 gene of 3 strains of PRRSV are shown in Table 2.1. qPCR reactions
were performed with SYBR Green supermix (Bimake, Houston, TX) using the ABI 7500 Fast
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platform (ThermoFisher Scientific). GAPDH was used as the housekeeping gene for gene
expression normalization. Data were processed with the software associated with ABI 7500.
Immunostaining and Western-Blotting (WB). The treated PAMs were rinsed with
cold DPBS. The cells were then fixed with 4% para-formaldehyde for 15 min. Following three
washes by DPBS, the cells were permeabilized with 0.5% TX-100 at room temperature for 5
min. The cells were blocked in 5% goat serum for 1 h at room temperature before they were
incubated with PE-conjugated anti-CD163 monoclonal antibody (Invitrogen) diluted 1:10,
phospho (p)-STAT3 at Tyr705 (1:100, Cell Signaling Technology, Danvers, MA), or with
PRRSV antibody SDOW17-F (1:500, RTI, LLC, Brookings, SD) at 37 °C for 2 h. The cells were
then counter-stained with DAPI (Invitrogen) for 5 min and washed. The fluorescence was
observed with an inverted Nikon fluorescence microscope and a Nikon A1R confocal
microscope.
For WB, whole cell proteins were isolated from PAMs at indicated time points. Briefly,
the cells were rinsed twice with cold PBS. After removing the PBS, cold RIPA buffer
(ThermoFisher Scientific) supplemented with 1% (v/v) protease and phosphatase inhibitors was
added to the cells and placed on ice for 5 min. Protein concentrations were determined using
Pierce BCA Protein Assay Kit (ThermoFisher Scientific). Equal amount of denatured proteins
from each sample were separated on 10% SDS-PAGE and transferred onto a PVDF membrane.
The membrane was incubated with 5% skim milk to block nonspecific binding before incubation
with anti-CD163 antibody (1:750; Abcam, Cambridge, MA), anti-phospho-STAT3 at Tyr705
(1:1,000), or anti- GAPDH antibody (1:2,000; Cell Signaling Technology) overnight at 4 °C.
After washing with 1×T-BST, the membrane was incubated with HRP-conjugated secondary
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antibody for 1 h at room temperature, and image developed with ECL Blotting Substrates (BioRad) and visualized under the ChemiDox XRS Image System (Bio-Rad).
PRRSV Infection and Viral Titration Assays. For PRRSV infection of PAM cells, PAMs
were seeded one day prior to infection. Cells were inoculated with one of the 3 strains of PRRSV
at multiplicity of infection (MOI) of 0.1 for 1 h. After removing the inoculum, the cells were
washed once with DPBS. The cells were incubated with DMSO or Cpt during the 24 – 48 h preinoculation period or the 21-24 h post-inoculation period. A detectable, rapid PRRSV
amplification stage in infected PAMs occurs between 12-36 h post inoculation before reaching a
plateau for titer (Burkard et al., 2017). We chose the 21 h time- point in the middle of the
dynamic stage to measure the inhibitory effect on viral replication by Cpt. The cell medium
supernatant was stored at -80 °C until future titration assay. The PRRSV titer in the culture
supernatant was determined by the inoculation of 10 - fold serially diluted supernatant in
quadruplicate into MARC-145 cells seeded in 48-well plates. The inoculum was removed from
cells after 2 h and replaced with 0.5 mL of DMEM supplemented with 2% FBS, 2 mM
Glutamax, 0.1 mM MEM Non-Essential Amino Acids, and 50 U/mL penicillin and 50 µg/mL
streptomycin (Invitrogen) to each well. Cells were cultured at 37 °C for 6 days and the wells
with cytopathic effect were recorded. The titer was calculated using the Reed and Müench
method (Reed and Muench, 1938) and expressed as median tissue culture infectious dose
(TCID50)/mL.
Statistics analysis. All experiments were performed at least 3 times. Data were analyzed
by one-way ANOVA with Tukey’s post hoc comparison or by paired t-test. Data were expressed
as mean ± sd and p < 0.05 was considered to be significant.
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2.3

Results
IL-10 Stimulates CD163 Transcription and Translation in PAMs. We first tested if

IL-10 could stimulate CD163 transcription and protein expression in pig cells. Incubation with
100 ng/mL of porcine IL-10 for 2 h and 24 h stimulated STAT3 activity in primary PAMs, as
indicated by the increased expression of STAT3 direct target – SOCS3 (Hutchins et al., 2015;
O’Brown et al., 2015) detected by quantitative reverse transcription – polymerase chain reaction
(qRT-PCR) (Figure 2.1A). We further noticed that at 24 h, IL-10 treatment significantly
promoted CD163 gene expression compared with the bovine serum albumin (BSA) control (Ctl)
(Figure 2.1A). The IL-10 enhanced CD163 protein expression in PAMs was confirmed by
immunostaining after 24 h stimulation (Figure 2.1B). This can be explained by the IL-10
stimulated increase of phospho (p)-STAT3 at Tyr705 (Figure 2.1B). Thus, IL-10 stimulates
CD163 transcription and translation in PAMs.
Cpt Inhibits IL-10−Induced and Basal Level CD163 Expression in PAMs. We next
asked if inhibiting STAT3 would block the CD163 expression in pig cells. To target IL10/STAT3 pathway, we compared 3 previously described STAT3-specific inhibitors: 5, 15-DPP
(DPP) (Nakamura et al., 2015; Uehara et al., 2009), Stattic (Schust et al., 2006), and Cpt (Shin et
al., 2009), which were reported to inhibit STAT3 at concentrations of 5, 20, and 7 µM,
respectively (Figure 2.2A). The cytotoxicity of these compounds to PAMs was first determined
by MTT assay. Except for Cpt, obvious cytotoxicity was observed for the other 2 compounds at
24 h with concentrations at 10 µM (Stattic) or above 10 µM (DPP) (Figure 2.2A).
We then treated PAMs for 24 h using these compounds with adjusted concentrations (10
µM DPP, 5 and 7 µM Stattic, 7 and 20 µM Cpt), with or without IL-10 stimulation. Under these
conditions, we did not observe obvious STAT3 inhibitory effect by DPP or Stattic in PAMs
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(Figure 2.2B). However, we observed significant inhibition of basal level or IL-10 stimulated
STAT3 activity by 7 and 20 µM Cpt treatment, as measured by the expression of STAT3 target
SOCS3 (Figure 2.2B). Similarly, the basal level or IL-10 stimulated CD163 expression in PAMs
was significantly decreased by treatment with 7 and 20 µM Cpt, while DPP or Stattic treatment
showed little effect (Figure 2.2C). The inhibition of IL-10 stimulated STAT3 activity and CD163
protein level by Cpt was determined by Western-Blotting (WB) (Figure 2.2D). Also, PAMs cotreated with IL-10 and Cpt for 24 h exhibited obvious inhibition of IL-10 stimulated CD163
expression by immunostaining (Figure 2.2E). In addition to the inhibition of IL-10 stimulated
CD163 expression, we further verified that the basal expression level of CD163 protein in PAMs
was also inhibited by Cpt- treatment (Figure 2.2F). Therefore, the STAT3 inhibitor Cpt imposes
significant inhibitory effect to CD163 mRNA and protein expression in primary PAM cells.
Cpt Pre- or Pre- Plus Post-treatment Inhibits PRRSV infection of PAMs in vitro. We
then asked if inhibiting CD163 expression by Cpt could block or mitigate PRRSV infection of
pig cells. To this end, we first treated PAM cells for 48 h with 5 or 10 µM Cpt, followed by
inoculation of PRRSV VR-2332 strain for 1 h (MOI = 0.1). PAMs were lysed at 21 h post
inoculation and total RNAs were extracted to evaluate the PRRSV infection of PAMs. qRT-PCR
revealed that PRRSV infection was significantly inhibited in PAMs with 10 µM Cpt pretreatment (p = 0.003), which was consistent with the reduced CD163 expression in treated PAMs
(Figure 2.3A). The culture media from different treatments were collected at 21 h post
inoculation. Viral titration experiments were performed and showed that pre-treatment of PAMs
with 10 µM Cpt significantly reduced the viral titer in the culture medium (p = 0.024) (Figure
2.3B). These data indicate that Cpt pretreatment can inhibit the PRRSV infection and replication
in PAMs.
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We then questioned if Cpt could inhibit PRRSV infection of PAMs stimulated by IL-10.
PAMs were pretreated with DMSO, IL-10, Cpt, or IL-10 plus Cpt for 24 h, inoculated with
PRRSV VR- 2332 strain, and then immunostained for PRRSV at 24 h after. The results of these
tests further verified that Cpt pretreatment significantly reduced the percentage of PRRSV
infected PAM cells (Figures 2.3C, 2.3D). As expected, treatment with 100 ng/mL IL-10
increased the percentage of PRRSV infected PAMs (p = 0.015) (Figures 2.3C, 2.3D). However,
co-treatment with 10 µM Cpt offset the IL-10 stimulated increase of PRRSV infection of PAMs
(Figures 2.3C, 2.3D). Thus, Cpt pretreatment can inhibit the PRRSV infection of PAM cells even
in the presence of IL-10.
We further tested the effect of pretreatment with Cpt for 24 h plus post-inoculation
treatment for 21 h after viral inoculation of PAMs (pre- plus post-treatment). PAMs were treated
accordingly and lysed thereafter with total RNAs extracted to evaluate the PRRSV infection.
qRT-PCR analysis on lysed PAMs revealed that both 5 and 10 µM Cpt treatments significantly
inhibited PRRSV infection of PAMs (p = 0.003; p = 0) (Figure 2.3E). The viral-titration assay to
the culture media of treated PAMs further confirmed that the 10 µM Cpt treatment significantly
blocked PRRSV infection/replication in PAMs (p = 0.001), resulting in about 2 log10 reduction
of viral TCID50/mL titer compared to the control (Figure 2.3F).
Cpt Pre- Plus Post-Treatment Inhibits the Infection of Several PRRSV Strains, and
Cpt Post-infection Treatment Alone Also Inhibits PRRSV Infection of PAMs in vitro. To
determine whether Cpt can also suppress the replication of other PRRSV strains within and
across genotypes, Lelystad (LY) (type I strain) and SDSU73 (type II strain) PRRSV were used to
infect PAMs. The PAMs were treated with Cpt for 24 h before inoculation and then for 21 h after
virus inoculation. The cells were lysed and total RNAs were extracted to measure the PRRSV
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infection of PAMs. qRT- PCR revealed that the replication of SDSU73 and LY strains were both
inhibited by 5 µM or 10 µM Cpt (Figure 2.4A). Titration of the 21 h viral supernatants showed
that 10 µM Cpt significantly suppressed the infection/replication of both SDSU73 and LY strains
in PAMs (p = 0.002; p = 0), with more than 1 log reduction of viral TCID50/mL titer compared
with the controls (Figure 2.4B). Taken together, our data demonstrated that Cpt treatment
inhibited the infection/replication of 2 strains of type II PRRSV as well as Lelystad, the
prototype strain of type I PRRSV in PAMs. We further questioned if the Cpt-treatment of PAMs
after PRRSV inoculation (posttreatment alone) could also inhibit the viral infection. Cpt was
supplemented at 5 or 10 µM to the culture media of PAMs after 1 h PRRSV VR-2332
inoculation. We performed immunostaining at 24 h posttreatment and found that treatment with
both 5 and 10 µM Cpt posttreatments significantly reduced the percentage of PRRSV-infected
PAM cells at 24 h post-inoculation (Figures 2.4C, 2.4D). Total RNAs were also extracted at 21 h
after Cpt treatment and the culture media from different conditions were collected. qRT-PCR
revealed that post-inoculation treatment of PAMs with 5 or 10 µM Cpt significantly inhibited
PRRSV infection of PAMs compared to the control (p = 0.007; p = 0.006), which was consistent
with the suppressed CD163 expression in PAMs (Figure 2.4E). Viral titration of the culture
media of treated PAMs further showed that 5 or 10 µM Cpt posttreatment after infection
significantly reduced PRRSV titer in the culture media (p = 0.04) (Figure 2.4F). Treatment of
PAMs with DMSO alone did not affect the outcome of PRRSV infection/replication in PAMs
(Figure 2S.1). Thus, Cpt-treatment of PAMs after the PRRSV inoculation also inhibits the
infection and replication of PRRSV in PAMs.
Inflammatory Responses in PRRSV-infected PAMs to Cpt. Some inflammatory
cytokines were measured in the 24 h pre-treated plus 21 h post-treated PRRSV-infected PAMs
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(Figure 2.5). Compared to the uninfected PAMs, VR-2332 and Lelystad PRRSV elevated
inflammatory IL-10 mRNA in the PAMs by 9-fold and 1.6-fold, respectively. The proinflammatory IL-1β, IL-12p40, and IFNβ mRNAs in the PAMs were increased by at least 13fold, 41-fold, and 2000-fold upon infection by either VR-2332 or Lelystad infection. Cpt
inhibited expression of these cytokines in the PRRSV-infected PAMs in a dose-dependent
manner. In the VR-2332-infected PAMs, Cpt decreased IL-1β, IL-10, IL-12p40, and IFNβ
mRNAs by at least 1-fold, 3-fold, 9-fold, and 4.5-fold, respectively compared to the infected but
untreated PAMs. With regard to the Lelystad-infected PAMs, the Cpt inhibitory effect on
cytokine mRNAs was less dramatic but demonstrated a similar pattern compared to Cpt effect on
VR-2332-infected PAMs.

2.4

Discussion
PRRS is considered one of the most economically significant disease across world swine

industry. Despite the fact that many MLVs or inactivated vaccines against PRRSV have been
licensed in various regions depending on the circulating strains, and tremendous efforts to
investigate more efficacious vaccines, vaccines that provide cross-protection against
heterologous PRRSV strains are still lacking. Meanwhile alternative or adjunct methods to
PRRSV vaccines are worthy of investigation to mitigate the adverse effects on the swine herd
caused by PRRS. CD163, a type I scavenger receptor exclusively expressing on cells of
monocyte-macrophage linage, has been well confirmed to be the key and universal receptor for
diverse PRRSV strains (Burkard et al., 2017; Whitworth et al., 2015). Different approaches have
been explored to block the expression of porcine CD163, including gene knockout, mRNA
knockdown by microRNA, or stimulation of acute CD163 protein shedding by LPS and
metalloproteinase (Calvert et al., 2007; Gao et al., 2013; Guo et al., 2014; Whitworth et al.,
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2015). Inhibiting CD163 expression in PAMs by targeting its regulatory signaling pathways with
natural or synthetic compounds hold the potential to be a unique, practical, and economical
approach to curtailing PRRS. In this research, we showed that CD163 expression was
upregulated by IL-10 stimulated STAT3 in pig cells. Furthermore, we demonstrated that the
natural compound and selective STAT3 inhibitor Cpt significantly inhibited CD163 expression
in PAMs, the primary target of in vivo productive PRRSV infection. We further demonstrated
that Cpt treatment of PAMs pre- or post-PRRSV inoculation could significantly inhibit type I
and type II PRRSV infection. Previous studies show that CD163 mainly mediate PRRSV
uncoating rather than viral internalization to the PAMs for productive infection (Van Gorp et al.,
2008, 2009; Vanderheijden et al., 2003). In our study, Cpt treatment post viral inoculation
inhibited CD163 expression and therefore suppressed PRRSV replication in PAMs significantly,
reconfirming that a crucial PRRSV replication step is blocked by targeting CD163. Future
investigation into the exact viral replication step blocked by Cpt-treatment is warrantied. Our
study identified a new potential approach to controlling PRRSV infection in pigs.
Natural compounds selectively targeting certain signaling pathways have emerged as
valuable resources to treat human diseases with increased efficacy and less cytotoxicity (Angulo
et al., 2017; Ranjan et al., 2015; Wang et al., 2018b). Cpt is a natural compound derived from the
Chinese herbal medicine Salvia miltiorrhiza (Danshen) (Chen et al., 2014; Shin et al., 2009). The
safety of Cpt orally administered to rodents has been evaluated with no obvious adverse effects
(Liu et al., 2015; Zhang et al., 2012), with significant effects against acute lung injury induced by
lipopolysaccharide, improved symptoms of Alzheimer’s disease and atherosclerosis in various
mouse models (Liu et al., 2015; Mei et al., 2009; Tang et al., 2014). Also, although CD163
knockout pigs are PRRSV-resistant, potential long-term side effects on pig health and
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development by the permanent deletion of CD163 gene still need to be evaluated. Inhibition of
CD163 by modulating signaling pathway activity is reversible upon withdrawn of these
compounds, providing a flexible alternative intervention to prevent PRRSV infection. It was
recently reported that the CD163 abundance level on cell surface is pivotal for effective PRRSV
infection (Wang et al., 2018a). This evidence is in line with the significance of this study that
Cpt, a natural compound inhibits PRRSV infection by reducing the expression of CD163 in
PAMs and may be readily applicable in vivo. It would be of interest to further screen other
natural STAT3 inhibitors as well as to test the in vivo efficacy of Cpt to control PRRSV infection
in pigs.
In line with previous studies (Genini et al., 2008; Hou et al., 2012), Our study showed
that infection by VR-2332 and Lelystad, the prototype strains of type I and type II PRRSV,
respectively, both significantly increased IL-10 transcription in the PAMs. Meanwhile, Cpt
drastically inhibited the PRRSV-infection-induced IL-10 transcription. IL-10 is a potent
immunosuppressive cytokine that interacts with various immune cells, thus inhibiting innate and
adaptive immunity, particularly the cell-mediated immune responses (Couper et al., 2008). IL-10
induction in pigs following PRRSV infection is believed to be a focal mechanism that the
PRRSV vaccine efficacy is compromised (Thanawongnuwech and Suradhat, 2010).
Additionally, the pro-inflammatory cytokines in PAMs induced by PRRSV infection was
substantially inhibited by Cpt treatment in this study, which is consistent with previous studies
showing Cpt suppresses production of pro-inflammatory cytokines by inhibiting NF-κB
signaling and MAPK signaling pathways (Maione et al., 2018; Tang et al., 2011). Altogether,
these data suggest Cpt to be a potent immunoregulator in the PRRSV-infected pig cells. Future
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investigation of Cpt’s potential to be a vaccine adjuvant in the control of PRRS is worthy of
carrying out.
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Table 2. 1 The sequences of primers for qRT-PCR in this study.

a

Primer group and namea.
Primers for qRT-PCR
STAT3-F

TCGGAACGTGGGATCAAGTG

STAT3-R

TCTCTGCCAGTGTGCTCAAC

SOCS3-F

CAGCTCCAAGAGCGAGTACC

SOCS3-R

TCACGGCGCTCCAGTAGAAG

CD163-F

GCCCCTCAGAGGAGACATGG

CD163-R

CCGTACCAGATCTCCACACG

GAPDH-F

CATCCTGGGCTACACTGAGG

GAPDH-R

GCTTGACGAAGTGGTCGTTG

VR2332-F

AAACCAGTCCAGAGGCAAGG

VR2332-R

GCAAACTAAACTCCACAGTGTAA

SDSU73-F

CCCTAGTGAGCGGCAATTGTGTC

SDSU73-R

GGCGCACAGTATGATGCGTC

LY-F

AAGATGACATCCGGCACCAC

LY-R

CCGGCAGCATAAACTCAACCTG

Sequence (5’ → 3’)

F, forward primer, R, reverse primer.
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Figure 2. 1: IL-10 pathway regulates CD163 expression in PAMs. (A) qRT-PCR for PAMs
treated with BSA (Ctl) or 100 ng/mL porcine IL-10 for 2 or 24 h. Values are normalized with
GAPDH. Bars represent mean±sd of 3 independent experiments. PAMs of the 3 repeats were from
one donor. P values were calculated using paired t-test. An asterisk indicates a comparison with
the indicated control. *: p < 0.05. **: p < 0.01. PAMs of the 3 repeats were from one donor. (B)
Immunostaining of PAMs treated for 24 h with BSA Ctl or 100 ng/mL IL-10. Bar = 120 µm.
Inserted figures: Confocal images with overlay of DAPI (blue) and CD163 (red), or p-STAT3
(Green) and CD163 (Red). Bar = 8 µm.
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Figure 2. 2: Cpt inhibits IL-10 pathway activity and CD163 expression in PAMs. (A) Upper:
Chemical structures of the 3 compounds. Lower: MTT assay of PAMs treated with the compounds
for 24 h at various concentrations. Upper X-axis: percent concentration of DMSO. Lower X-axis:
concentration of the compounds. Values represent mean±sd of 3 independent experiments. PAMs
of the 3 repeats were from one donor. (B) qRT-PCR for SOCS3 expression in PAMs treated with
various concentrations of small molecules with or without 100 ng/mL porcine IL-10 (Ctl) for 24
h. Values are normalized with GAPDH. Bars represent mean±sd of 4 independent experiments.
PAMs of the 4 repeats were from one donor. P values were calculated using Tukey’s post hoc
comparison. An asterisk indicates a comparison with the indicated control. (C) qRT-PCR for
CD163 expression in PAMs treated as described in B. Values are normalized with GAPDH. Bars
represent mean±sd of 4 independent experiments. PAMs of the 4 repeats were from one donor. P
values were calculated using Tukey’s post hoc comparison. An asterisk indicates a comparison
with the indicated control. (D) WB (upper) and densitometry data (lower) for total proteins of
PAMs stimulated with or without 100 ng/mL IL-10 for 24 h, and IL-10 with co-treatment of 20
µM Cpt. Bars represent mean±sd of 4 independent experiments. PAMs of the 4 repeats were from
4 donors. (E) Immunostaining of PAMs treated for 24 h with BSA Ctl or 100 ng/mL IL-10, or IL10 plus 20 µM Cpt. Bar = 120 µm. Inserted figures: Confocal images with overlay of DAPI (blue)
and CD163 (red). Bar = 8 µm. F. WB (upper) and densitometry data (lower) for total proteins of
PAMs treated with DMSO Ctl or with 20 µM Cpt for 24 h. Bars represent mean±sd of 3
independent experiments. PAMs of the 3 repeats were from 3 donors, P value was calculated using
paired t-test *: p < 0.05; **: p < 0.01; ***: p < 0.001.
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Figure 2. 3: Cpt pre- or pre- plus post-treatment inhibits PRRSV infection of PAMs. (A)
qRT-PCR for CD163 and VR-2332 PRRSV expression in PAMs pre-treated with DMSO or Cpt
for 48 h, and harvested at 21 h post PRRSV VR-2332 strain inoculation (MOI = 0.1). Controls
were treated with 0.1% DMSO vehicle equivalent to what used by 10 µM Cpt. Values are
normalized with GAPDH. Bars represent mean±sd of 3 independent experiments. PAMs of the 3
repeats were from one donor. P values were calculated using Tukey’s post hoc comparison. An
asterisk indicates a comparison with the indicated control. (B) TCID50 value for PRRSV titer in
the culture supernatant of PAMs treated the same as described in A. Values represent mean±sd of
3 independent experiments. PAMs of the 3 repeats were from one donor. P values were calculated
using Tukey’s post hoc comparison. An asterisk indicates a comparison with the indicated control.
(C) Representative images for PRRSV in PAMs after 24 h IL-10 and/or Cpt pretreatment and
immunostained at 24 h post-inoculation. NC: non-infected DMSO treated negative control. PC:
PRRSV VR-2332 strain infected positive control, DMSO treated. Inserted figures: Confocal
images with overlay of DAPI (blue) and PRRSV (green). Bar = 8 µm. (D) The percentage of
PRRSV positive PAMs treated as described in C. Values represent mean±sd of 3 independent
experiments. PAMs of the 3 repeats were from one donor. (E) qRT-PCR for CD163 and PRRSV
expression from PAMs pretreated for 24 h by DMSO or Cpt followed by 21 h posttreatment after
PRRSV VR-2332 strain inoculation (MOI = 0.1). Values are normalized with GAPDH. Bars
represent mean±sd of 3 independent experiments. PAMs of the 3 repeats were from one donor. P
values were calculated using Tukey’s post hoc comparison. An asterisk indicates a comparison
with the indicated control. (F) TCID50 value for VR-2332 PRRSV titer in the culture supernatant
of PAMs treated the same as described in E. Values represent mean±sd of 3 independent
experiments. PAMs of the 3 repeats were from one donor. P values were calculated using Tukey’s
post hoc comparison. An asterisk indicates a comparison with the indicated control; *: p < 0.05;
**: p < 0.01; ***: p < 0.001.
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Figure 2. 4: Cpt pre- plus post-treatment inhibits the infection of several PRRSV strains, and
Cpt-posttreatment alone also inhibits PRRSV infection of PAMs in vitro. (A) qRT-PCR for
PRRSV expression from PAMs pretreated for 24 h with DMSO or Cpt followed by 21 h
posttreatment after the PRRSV SDSU73 or LY strain inoculation (MOI = 0.1). Values are
normalized with GAPDH. Bars represent mean±sd of 3 independent experiments. PAMs of the 3
repeats were from one donor. P values were calculated using Tukey’s post hoc comparison. An
asterisk indicates a comparison with the indicated control. (B) TCID50 value for PRRSV titer in
the culture supernatant of PAMs treated the same as described in A. Values represent mean±sd of
3 independent experiments. PAMs of the 3 repeats were from one donor. P values were calculated
using Tukey’s post hoc comparison. An asterisk indicates a comparison with the indicated control.
(C) Representative immunostaining pictures for PRRSV in PAMs after 24 h Cpt posttreatment
after viral inoculation of PAMs. NC: non-infected, DMSO treated negative control. PC: PRRSV
strain VR-2332 infected, DMSO treated. Inserted figures: Confocal images with overlay of DAPI
(blue) and PRRSV (green). Bar = 8 µm. (D) The percentage of PRRSV VR-2332 positive PAMs
treated the same as described in C. Values represent mean±sd of 3 independent experiments. PAMs
of the 3 repeats were from one donor. P values were calculated using Tukey’s post hoc comparison.
An asterisk indicates a comparison with the indicated control. (E) qRT-PCR for CD163 and
PRRSV expression from PAMs treated for 21 h post PRRSV VR-2332 strain inoculation (MOI =
0.1). Values are normalized with GAPDH. Bars represent mean±sd of 3 independent experiments.
PAMs of the 3 repeats were from one donor. P values were calculated using Tukey’s post hoc
comparison. An asterisk indicates a comparison with the indicated control. (F) TCID50 value for
VR-2332 PRRSV titer in the culture supernatant of PAMs treated the same as described in E.
Values represent mean±sd of 3 independent experiments. PAMs of the 3 repeats were from one
donor. P values were calculated using Tukey’s post hoc comparison. An asterisk indicates a
comparison with the indicated control.; *: p < 0.05, **: p < 0.01; ***: p < 0.001.
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Figure 2. 5: Inflammatory response of PRRSV-infected PAMs to Cpt treatment. PAMs were
pre-treated with DMSO or Cpt for 24 h and then incubated with or without PRRSV (VR-2332 or
Lelystad) for 1 h (MOI = 0.1). The cells were further post-treated with DMSO or Cpt for 21 h.
Total RNA was extracted from cells at 21 h post inoculation. Relative expression of IL-1β, IL-10,
IL-12p40, and IFNβ mRNA were assessed using qRT-PCR. Values were normalized with GAPDH.
Bars represent mean±sd of 3 independent experiments. PAMs of the 3 repeats were from one donor.
P values between the uninfected group and virus group were calculated using paired t-test. P values
between virus group and the two Cpt groups were calculated using Tukey’s post hoc comparison.
*: p < 0.05, **: p < 0.01, ***: p < 0.001, ns: non-significant.
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Figure 2S. 1: DMSO does not affect PRRSV infection in PAMs. TCID50 value for PRRSV titer
in the culture supernatant of PAMs treated for 21 h post PRRSV strain VR-2332 inoculation (MOI
= 0.1) with or without 0.1% DMSO (equivalent to the amount used in 10 µM Cpt). Values represent
mean±sd of 3 independent experiments. PAMs of the 3 repeats were from one donor. P values
were calculated using paired t-test. An asterisk indicates a comparison with the indicated control.
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Abstract Porcine reproductive and respiratory syndrome (PRRS) is an economically significant
disease to the global pork industry and its causative agent is PRRS virus (PRRSV). Currently,
vaccines, used to control this disease, can only confer effective protection against genetically
homologous PRRSV strains, therefore, studies on alternative approaches to combatting this
panzootic, are of great interest. Through an artificial intelligence molecular screen (AIMS)
program, we obtained a set of small molecular compounds predicted to target the scavenger
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receptor cysteine-rich domain 5 (SRCR5) of CD163, which is the key receptor for PRRSV
infection. Using a cell-based bimolecular fluorescence complementation (BiFC) assay, we
identified one synthetic compound (designated as B7) that significantly inhibits the proteinprotein interaction (PPI) between the PRRSV glycoprotein (GP2a or GP4) and CD163-SRCR5
domain. We further demonstrated that compound B7 significantly inhibits PRRSV infection of
porcine alveolar macrophages (PAMs) in vitro, the primary natural host cells of PRRSV in a
dose-dependent manner. B7 exhibited similar efficacy in inhibiting the infection by multiple
PRRSV strains in vitro. Further characterization of antiviral efficacy of B7 analogues identified
several analogues which are also potent antiviral agents against PRRSV infection in vitro.
Structural comparison among these compounds suggested that the 3-(morpholinosulfnyl)aniline
moiety of B7 or the 3-(piperidinylsulfonyl)anilino moiety in a B7 analogue may be important for
the inhibitory effect against PRRSV infection. Our study revealed a new approach to potentially
preventing PRRSV infection in pigs by blocking the PRRSV-CD163 interaction using chemical
compounds.
Keywords infection, SRCR5, PPI, PAMs, analogue

3.1

Introduction
Porcine reproductive and respiratory syndrome (PRRS) is a panzootic infectious disease

of pigs, causing major economic losses to the world-wide swine industry. The causative virus of
PRRS (PRRSV) is an enveloped, positive-sense, single-stranded RNA virus belonging to
Arteriviridae family, Nidovirales order (Benfield et al., 1992; Cavanagh, 1997). PRRSV
infection may cause severe reproductive failure in sows and respiratory disorders in piglets
(Wang et al., 2018). These syndromes are frequently accompanied by secondary infections with
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even greater clinical manifestations and mortality for pigs of all age (Tian et al., 2007;
Zimmerman et al., 1997). However, due to the high heterogeneity of PRRSV, broadly effective
vaccines are lacking (Meng, 2000; Murtaugh et al., 2010; Nan et al., 2017). New approaches are
needed to combat the PRRS panzootic to mitigate the devastating consequences of this disease.
Productive PRRSV infection occurs primarily in porcine alveolar macrophages (PAMs)
residing in the lungs (Murtaugh et al., 2002). CD163, a macrophage-specific membrane scavenge
receptor, is a key receptor for PRRSV infection (Calvert et al., 2007; Delrue et al., 2010; Lee et
al., 2010; Weingartl et al., 2002). The indispensability of CD163 expression for PRRSV
infection was confirmed by knockout studies showing pigs lacking functional CD163 are
resistant to PRRSV challenge (Wells et al., 2017; Whitworth et al., 2015). Out of the 9
extracellular scavenger receptor cysteine-rich (SRCR) domains in CD163, the fifth SRCR
domain (SRCR5) was found essential for PRRSV infection (Van Gorp et al., 2010) and
monocytes/macrophages from pigs with a SRCR5 deletion of the CD163 gene show complete
resistance to PRRSV infection (Burkard et al., 2017). Cellular pull-down assay revealed that
minor glycoproteins GP2a and GP4 of PRRSV specifically interact with the CD163 molecule,
and they bind the CD163 extracellular but not transmembrane or cytoplasmic region (Das et al.,
2010). Thus, it is reasonable to assume that the CD163-SRCR5 domain will directly interact with
the PRRSV glycoproteins. However, assays studying protein-protein interactions (PPIs) between
the CD163-SRCR5 domain and PRRSV glycoproteins have not been reported. A number of
small molecules have been identified to effectively block the entry of various viruses infecting
humans by binding and antagonizing the host cell receptors/co-receptors (Briz et al., 2006;
Kaneko et al., 2018; Kaneko et al., 2015; Kuritzkes, 2009; Nkongolo et al., 2014; Qian et al.,
2009; Wang et al., 2015; Watashi et al., 2014). However, small molecules targeting the PPIs
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between PRRSV and CD163 receptor have not been reported. A recent study on pig CD163 Xray crystal structure compared porcine CD163-SRCR5 domain with other members of the
scavenger receptor cysteine-rich superfamily (M2BP and CD5) and revealed that the loop 5-6
region within porcine CD163-SRCR5 domain may contribute to the receptor specificity of
porcine CD163 for PRRSV infection (Ma et al., 2017). Furthermore, structure-based sitedirected mutagenesis elucidated a charged residue, the arginine residue at position 561 (Arg561)
in the loop 5-6 region is important for PRRSV infection (Ma et al., 2017). This raises the
possibility that targeting porcine CD163-SRCR5 domain with small molecules may prevent
PRRSV infection. In this study, we established a BiFC assay to study the PPIs between PRRSV
glycoproteins and the porcine CD163-SRCR5 domain. Using this assay, we were able to test a
list of small molecules predicted to bind to the porcine CD163-SRCR5 domain and identify a
compound that inhibits the PPIs between the PRRSV glycoproteins and SRCR5. We further
characterize antiviral efficacy of this compound against PRRSV infection of PAMs. In addition,
we validated the same efficacy of various analogues of this compound and revealed possible
moieties that are important for inhibiting PRRSV infection.

3.2

Materials and Methods
Chemicals, Cells, and Viruses. All screening compounds were provided by Atomwise,

Inc (CA, USA) or purchased from MolPort, Inc (NY, USA). Porcine alveolar macrophages
(PAMs) were harvested from lungs of healthy 4–6-month old and PRRSV-negative
Landrace/Yorkshire cross pigs. Lungs were transferred on ice to Biosafety Level 2 cabinet.
Carefully injected warm PBS with 200 U/mL penicillin and 200 µg/mL streptomycin through the
major trachea bronchi into both sides of the lungs. Lungs were massaged and the
bronchoalveolar lavage fluid (BALF) was retrieved. The BALF was centrifuged at 400 g for 15
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minutes to pelletize PAMs. The PAMs were then washed twice with warm complete medium.
Cells were counted and frozen in 90% FBS (HI, Rocky Mountain Biologicals, Inc) and 10%
DMSO (Sigma). Cells were stored in Mr. Frosty Freezing Container (Nalgene, USA), and put at
-80 °C before being transferred to liquid nitrogen. PAMs were cultivated in RPMI-1640 (Gibco)
supplemented with 10% FBS (HI, Rocky Mountain Biologicals, Inc), 2 mM Glutamax
(Invitrogen), 0.1 mM MEM Non-Essential Amino Acids (Gibco), 1mM sodium pyruvate
(Gibco), 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco), and 0.5 µg/mL
Amphotericin B (Gibco). All PRRSV strains were propagated and titrated in MARC-145 cells.
AIMS Screen. Virtual screening was performed using AtomNet, the first deep neural
network for structure-based drug design trained to predict protein-ligand binding
affinity(Wallach et al., 2015). For targeting the interaction between the porcine CD163 and
PRRSV glycoprotein (GP2a or GP4), the X-ray structure of CD163-SRCR5 domain
(PDBID:5HRJ) was used to define a screening site centered around R561 comprising residues
C502, S503, D505, W540, A541, E543, A559, P560, R561, P562, D563, G564, and C566
(Figure 3S.2). The Mcule library of commercially available organic small molecule compounds
(~4M v20171018) was prepared and screened, as described previously(Hsieh et al., 2019), using
an ensemble of protein-ligand conformations. Each of the 4M molecules was scored and ranked
by AtomNet, following which a top set of 200 chemically diverse compounds was further
inspected for undesirable substructures and molecular properties before 74 compounds were
obtained for experimental testing.
Plasmid Construction. N terminus and C terminus of the truncated Venus-I152L were
inserted into vector backbone pMyc-CMV and pCMV-HA, constituting commercial plasmids
pBiFC- VN155(I152L) and pBiFC-VC155, respectively (Addgene, Watertown, MA, USA)
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(Kodama, Y. et al., Biotechniques, 2010). cDNA fragments for the scavenger receptor cysteinerich domain 2 (SRCR2) and SRCR5 of porcine CD163 receptor, and for VR-2332 PRRSV
glycoproteins GP2a and GP4 were amplified by RT-PCR. The amplified cDNA fragments of
SRCR2 or SRCR5 were sub-cloned into the pBiFC-VN155(I152L) vector digested with
EcoRI/BglⅡ. For constructions of GP2a and GP4 fusion proteins, cDNA fragments encoding
GP2a or GP4 were sub-cloned into the pBiFC-VC155 vector digested with EcoRI/BglⅡ. All
plasmid clones were verified by DNA Sanger sequencing.
BiFC Assay. HEK293T cells cultured in 12-well plates were transfected with appropriate
plasmids for each BiFC assay using FuGENE® 6 (Promega, Madison, WI, USA). After 4 h,
various concentrations of chemical compounds were added to the culture media. DMSO was
used as the vehicle control. Fluorescence images of treated cells at 24 h after plasmid
transfection were captured using an inverted Nikon fluorescence microscope. Fluorescence
intensity of treated cells was measured by ImageJ (https://imagej.nih.gov/ij/).
Cytotoxicity Assay. The cytotoxicity of selected screening compounds was determined
in PAMs, the principal host of productive PRRSV infection. Briefly, various concentrations of
the compounds were added to PAMs seeded in 24-well plates and incubated for 24 h. Then 50 µl
of the 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) labeling reagent (In
Vitro Toxicology Assay Kit, MTT based, Sigma-Aldrich) were added to each well and incubated
for 4 h before 500 µl of the solubilization solution was added into each well to fully dissolve the
formazan crystal by overnight incubation. The absorbance of samples was measured using a
spectrophotometry microplate reader at 600 nm. PAMs treated with DMSO served as controls.
Quantitative Reverse Transcription – PCR (qRT-PCR). For relative quantification of
PRRSV in PAMs, total RNA was extracted from PAMs infected with PRRSV using RNeasy
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Mini Kit (Qiagen, Germantown, MD) according to the manufacturer’s instruction. RNA
concentrations were measured using a Nanodrop spectrophotometer (Thermo Fisher Scientific).
Specific real time qPCR primers for the ORF7 gene of the four PRRSV strains and for porcine
GAPDH are shown in Table 3.2. GAPDH was used as the housekeeping gene for gene
expression normalization. Data were processed with the software associated with ABI 7500.
Western Blotting. Whole cell proteins were isolated from HEK293T cells. Briefly, the
cells were rinsed twice with cold PBS. After removing the PBS, cold RIPA buffer
(ThermoFisher Scientific) supplemented with 1% (v/v) protease and phosphatase inhibitors was
added to the cells and placed on ice for 5 min. Protein concentrations were determined using
Pierce BCA Protein Assay Kit (ThermoFisher Scientific). Equal amount of denatured proteins
from each sample were separated on 10% SDS-PAGE and transferred onto a PVDF membrane.
The membrane was incubated with 5% skim milk to block nonspecific binding before incubation
with Myc-Tag mouse monoclonal antibody (1:1000, Cell Signaling Technology, Danvers, MA)
or anti-GAPDH antibody (1:1,000; Cell Signaling Technology, Danvers, MA) overnight at 4 °C.
After washing with 1× T-BST, the membrane was incubated with HRP-conjugated secondary
antibody (Cell Signaling Technology, Danvers, MA) for 1 h at room temperature, and image
developed with ECL Blotting Substrates (Bio-Rad) and visualized under the ChemiDox XRS
Image System (Bio-Rad).
PRRSV Infection and Titration Assay. For PRRSV infection of PAM cells, PAMs
were seeded one day prior to infection. The cells were treated with DMSO as the control or with
the selected screening compounds (5-20 µM) for 4 h before inoculation, and for 24 h after
inoculation. Cells were inoculated with VR-2332, SDSU73, NADC30 or Lelystad PRRSV (MOI
= 0.1) for 1 h. The 24 h cell medium supernatant was stored at -80 °C until future titration assay.
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For PRRSV titration assay, MARC145 cells were seeded in 48-well plates and grew to
~80% confluency density before inoculation. Viral supernatants were prepared by 10-fold serial
dilution, and 100 µl of the dilutions was added per well in six replicates. Inoculum was removed
from cells after 2 h and replaced with 0.5 mL of DMEM supplemented with 2% FBS, 2 mM
Glutamax, 0.1 mM MEM Non-Essential Amino Acids, and 50 U/mL penicillin and 50 µg/mL
streptomycin (Invitrogen) to each well. Cells were cultured at 37 °C for 6 days and then the
cytopathic effects were recorded. The PRRSV titer was calculated using the Reid and Müench
method and expressed as median tissue culture infectious dose (TCID50/mL).
Statistical Analysis. All experiments were performed at least 3 times. Data were
analyzed by one-way ANOVA with Tukey’s post hoc comparison or by paired t-test. Data were
expressed as mean ± sd and p < 0.05 was considered to be significant.

3.3

Results
Establishment of BiFC Assays to Identify Small Molecules That Inhibit the PPI

between PRRSV and CD163. Using the previously described BiFC vector (Kodama and Hu,
2010) based on the N terminus (VN155(I152L), hereafter named VN) and C terminus (VC-155,
hereafter named VC) of the fragmented Venus-I152L, we established fusion protein constructs
between the porcine CD163 protein SRCR5 or SRCR2 domain and VN, and between the
PRRSV minor glycoprotein (GP2a or GP4) and VC (Figures 3.1A, 3S.1). We co-expressed these
plasmids in HEK293T cells to evaluate the PPIs between the SRCR5 domain and GP2a (or
GP4). In agreement with the validated critical role of CD163-SRCR5 in mediating the PRRSV
infection (Burkard et al., 2017; Van Gorp et al., 2010), the CD163-SRCR5/VN fusion protein
(SRCR5-VN) interacts with GP2a/VC and GP4/VC fusion protein, with strong fluorescence
detected under the microscope (Figures 3.1B, 3.1C, top panel). In contrast, the fusion protein of
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CD163-SRCR2 domain (SRCR2-VN), which is dispensable for the PRRSV infection and
PRRSV-CD163 interaction (Van Gorp et al., 2010), only showed background fluorescence when
co-expressed with GP2a/VC or GP4/VC fusion protein (Figures 3.1B, 3.1C, lower panel). These
data indicate that the porcine CD163-SRCR5 domain interacts directly with PRRSV
glycoproteins GP2a and GP4.
We then asked whether the BiFC assays we established could be used to identify small
molecules with potential to block the interaction between CD163 and PRRSV. A structure-based
virtual screening program named artificial intelligence molecular screen (AIMS) performed by
Atomwise, Inc. (San Francisco, CA) was used to screen 4 million compounds within a small
molecule library for affinity to the previously published 3-D protein structure of porcine CD163SRCR5 domain (Ma et al., 2017). A list of 74 small molecules were predicted most likely to bind
ensemble porcine CD163-SRCR5 domain by Atomwise, Inc. (San Francisco, CA). In the cellular
assays, we tested these compounds using our BiFC assay, to evaluate their potential of inhibiting
the PPI between GP2a and SRCR5. SRCR5-VN and GP2a/VC plasmids were co-transfected in
HEK293T cells. Four hours after the two plasmids were added, the screened small molecules
were administered individually to cells at 5 µM. At 24 h, fluorescence from reconstituted VenusI152L was captured under a fluorescence microscope and fluorescence intensity was quantified.
Of all the 74 small molecules, we identified an active compound designated herein as B7 (4Fluoro-2-methyl-N-[3-(3-morpholin-4-ylsulfonylanilino)quinoxalin-2-yl]benzenesulfonamide,
C25H24FN5O5S2, Figure 3.1D) that significantly inhibited the fluorescence in our assay (Figure
3.1E). We further verified that B7 also inhibited the PPI between PRRSV GP4 and SRCR5 using
the other BiFC assay (Figure 3.1F).
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Validation of the Function of Compound B7 to Inhibit the PRRSV Infection of
PAMs. Based on the demonstrated inhibitory effect of B7 compound on the interaction between
CD163-SRCR5 domain and PRRSV glycoproteins, we then asked whether this compound will
inhibit the PRRSV infection of PAMs. MTT assay at 24 h revealed that B7 compound is well
tolerated by PAMs at concentrations below 25 µM, with the lethal concentration, 50% (LC50)
calculated (Finney, 1952) at 81.7 µM (Figure 3S.3). Primary PAMs were then pre-treated with
B7 ranging from 0 – 20 µM for 4 h, followed by 1 h inoculation with PRRSV strain VR-2332
(MOI = 0.1). The infected PAMs were then continuously incubated with B7 compound at
various concentrations. At 24 h post inoculation (24hpi), total RNAs were extracted from PAMs.
Quantitative reverse transcription – PCR (qRT-PCR) revealed a dose-dependent inhibition of
PRRSV infection of PAMs by the B7 treatments (Figure 3.2A). Viral titration further confirmed
that B7 compound at concentrations between 10 µM and 20 µM reduced viral load in the 24hpi
supernatant substantially, with 2-3 log10 reduction in titer at 15 µM and 20 µM (p = 0; p = 0)
(Figure 3.2B). 15 µM and 20 µM B7 treatments exerted similar anti-PRRSV activity. 15 µM was
chosen for later assays considering to minimize compound cytotoxicity.
The antiviral effect of B7 compound was further tested on heterologous PRRSV strains.
PAMs were pre-treated with DMSO as the control or 15 µM B7 for 4 h, and inoculated with
PRRSV strains VR-2332, SDSU73, NADC30 (Type II) or Lelystad (Type I) for 1 h (MOI =
0.1), and continuously incubated with DMSO or 15 µM B7 for 24 h. qRT-PCR revealed that B7
significantly inhibited infection of PAMs for all the 4 PRRSV strains (p = 0.004; p = 0.008; p =
0.003; p = 0.001) (Figure 3.2C). This viral inhibitory effect is further confirmed by viral titration
assay showing that for all of the 4 strains, viral loads in 24hpi cell culture supernatant of the
infected PAMs were decreased by more than 2 log10 infectious units by 15µM B7 (p = 0.005; p =
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0.002; p = 0.003; p = 0.008) (Figure 3.2D). Thus, B7 compound provides PAMs with crossprotection against type I and type II PRRSV in vitro.
Evaluating Anti-PRRSV Activity of Small Molecules with Similar Chemical
Structure to B7 compound. B7 is a synthetic compound with its biological activities
undocumented previously. In order to examine the structural relevance of B7 molecule to the
PRRSV inhibition, we performed PubChem search for similar compounds and obtained an
additional 6 compounds structurally related to B7 (designated herein as B7-A1 to B7-A6, Figure
3.3A, Table 3.1). We first used our BiFC assay as described above to test if any of these B7
analogues can inhibit the PPI between CD163-SRCR5 domain and PRRSV GP2a protein.
Similar as B7 (p = 0), compounds B7-A1 to B7-A4 all significantly inhibited the PPI between
CD163-SRCR5 and PRRSV GP2a in our BiFC assay (p = 0; p = 0; p = 0.001; p = 0) (Figures
3.3B, 3.3C). Interestingly, shifting the 3-(morpholinosulfonyl)anilino moiety of B7 to 4(morpholinosulfonyl)anilino position (B7-A2), or to 3-(piperidinylsulfonyl)anilino moiety (B7A4, blue circle) does not eliminate the compound activity of inhibiting the PPI between CD163SRCR5 and PRRSV GP2a (Figures 3.3B, 3.3C). However, replacing the 3(piperidinylsulfonyl)anilino or 3-(morpholinosulfonyl)anilino moiety with morpholine in
compounds B7-A5 and B7-A6 (Figure 3.3A, red circle) completely blocked their ability of
inhibiting the PPI between CD163-SRCR5 and PRRSV GP2a (Figures 3.3B, 3.3C).
We further asked whether these active small molecules in the BiFC assay inhibit PRRSV
infection of PAMs. MTT assay at 24 h revealed that these small molecules have no obvious
cytotoxic effect on PAMs at 15 µM (Figure 3S.4). PAMs were then pre-treated with these active
small molecules (B7-A1 to B7-A4) or B7-A5 (as a reference) at 15 µM individually for 4 h and
inoculated with PRRSV strain VR-2332 for 1 h (MOI=0.1). The cells were then continuously
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incubated with 15 µM of the same small molecules. Total RNAs were extracted from infected
PAMs at 24 hpi, and qRT-PCR revealed that similar as B7 (p = 0), these active small molecules
in the BiFC assay (B7-A1 to B7-A4) all inhibited the PRRSV RNA level in the treated PAMs (p
= 0.039; p = 0.022; p = 0.048; p = 0.01) (Figure 3.3D) compared with the control. Treatment
with B7-A5, however, failed to inhibit PRRSV RNA level in the infected PAMs (Figure 3.3D).
Titration of progeny PRRSV in the 24 hpi cell culture supernatant of infected cells further
confirmed that compounds B7-A1 through B7-A4 but not B7-A5 inhibited PRRSV infection of
PAMs (p = 0; p = 0; p = 0; p = 0; p = 0.965) (Figure 3.3E). We also speculated that the 3(morpholinosulfonyl)anilino moiety (in B7 and B7-A1 through B7-A3) and the 3(piperidinylsulfonyl)anilino moiety (in B7-A4) could be pharmacophores important for the antiPRRSV activity.
3-(morpholinosulfonyl)anilino or 3-(piperidinylsulfonyl)anilino Alone in A Small
Molecule Does Not Inhibit PRRSV Infection. We also noticed that removing the methyl and/or
fluoro groups from the benzenesulfonamide moiety of B7 (compound B7-A3) weakened the
compound inhibitory activity in our BiFC assay (Figures 3.3B, 3.3C) and PRRSV infection assay
(Figures 3.3D, 3.3E), though the difference is not as dramatic as modifying the 3(morpholinosulfonyl)anilino moiety. In order to determine if the 3-(morpholinosulfonyl)anilino
or 3-(piperidinylsulfonyl)anilino moiety alone in a small molecule is sufficient to suppress the
PRRSV infection, we purchased 2 compounds with either of these 2 moieties as the only
chemical constituent. We designated them as B7-A7 and B7-A8, respectively (Figure 3.4A). We
pre-treated PAMs with 15 µM of each molecule for 4 h prior to 1 h VR-2332 PRRSV inoculation
(MOI=0.1). The cells were then further post-treated with either compound for 24 h. Titration of
progeny PRRSV in the 24 hpi cell culture supernatant of the treated cells revealed that neither of

82

these 2 compounds inhibited PRRSV infection of PAMs (Figure 3.4B). Therefore, while these 2
moieties are functionally critical for B7 and its analogues, the presence and modification of other
chemical structures (e.g., benzenesulfonamide) could also be important for the inhibition of
PRRSV infection.
B7 Compound Has Its Anti-PRRSV Activity Exclusively during Post-inoculation
Period. We have validated the inhibitory effect of B7 on PRRSV infection upon pre- and postinoculation treatments. We further asked whether treatment with B7 either pre- or postinoculation will have any significant effect on PRRSV infection. PAMs were either treated with
15 µM B7 for 4 h followed by PRRSV strain VR-2332 inoculation (MOI=0.1) with no posttreatment, or treated with 15 µM B7 for 24 h post PRRSV-inoculation (MOI=0.1) without pretreatment. At 24 hpi, we evaluated viral RNA in PAMs and the PRRSV titer in cell culture
supernatant. qRT-PCR showed that B7 post-treatment alone exhibited comparatively inhibitory
effect on PRRSV infection to the pre- plus post-treatment (Figure 3.5A). This finding was further
supported by titration of progeny PRRSV in the 24hpi cell culture supernatant (Figure 3.5B).
However, the inhibitory effect of B7 on PRRSV infection was very negligible if incubated with
cell only prior to inoculation (Figures 3.5A, 3.5B). This led us to speculate B7 did not exert
inhibitory effect on PRRSV infection prior to PRRSV inoculation, the B7 binding to the cells are
weak and reversible, and that its inhibitory effect is transient upon withdrawal of B7 compound.
We further treated PAMs with DMSO as the Ctrl or 15 µM B7 for 4 h prior to VR-2332
or Lelystad PRRSV inoculation for 1h (MOI=0.1). RNA was extracted from the PAMs
immediately after the inoculation and the level of cell-bound viral RNA was relatively quantified
by RT-qPCR. These data suggested B7 pretreatment did not inhibit viral binding to the PAMs
(Figure 3.5C). To this end, we asked whether the lack of inhibitory effect of B7 pretreatment on
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viral binding was due to the absence of B7 during the 1h PRRSV inoculation (Figures, 3.5A,
3.5B). PAMs were then inoculated with VR-2332 PRRSV (MOI = 0.1) for 1 h during which the
cells were also treated with DMSO as the Ctrl or 15 µM B7. After the inoculation, the cells were
immediately subject to RNA extraction (0 hpi), or incubated without any treatment for 24 h
before RNA extraction (24 hpi). The viral RNAs at 0 hpi and 24 hpi were relatively quantified by
RT-qPCR. The results indicated viral binding to the PAMs were not significantly inhibited even
if the PAMs were consistently exposed to B7 compound during the inoculation (Figure 3.5D).
Figure 3S.5 further suggested B7 treatment did not significantly affect PRRSV infectivity during
the 1 h inoculation, ruling out the possibility that infectivity lost might interfere in the viral
binding. Altogether, B7 compound has its anti-PRRSV activity exclusively during the postinoculation period.

3.4

Discussion
Although the porcine CD163-SRCR5 domain has been identified to be critical for

PRRSV infection (Burkard et al., 2017; Van Gorp et al., 2010) and PRRSV glycoproteins GP2a
and GP4 have been validated to specifically interact with porcine CD163 receptor (Das et al.,
2010), no study has been performed to validate whether porcine CD163-SRCR5 domain directly
interacts with PRRSV glycoproteins during the infection. Using BiFC assay, we demonstrated
that the CD163-SRCR5 domain can interact directly with PRRSV glycoprotein GP2a and GP4.
We further identified a small molecule designated as B7 which can block the interaction between
CD163-SRCR5 domain and PRRSV GP2a/GP4, consequently inhibiting the infection of PAMs
by type I and type II PRRSV in vitro. In addition, we identified several active B7 analogues with
anti-PRRSV activity. The high consistency of the infection assay data with the BiFC assay
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results suggested our BiFC assay to be reliable tool for preliminarily screening small molecules
for anti-PRRSV activity.
We found that B7 post-inoculation treatment inhibited PRRSV infection to a similar
degree as the B7 pre- plus post-inoculation treatment, while the B7 pre-inoculation treatment had
negligible anti-PRRSV effect (Figures 3.5 A, 3.5B). This suggests a reversible association of B7
compound with porcine CD163-SRCR5 domain: upon the removal of B7 compound, the
inhibition in the interactions between PRRSV glycoproteins and porcine CD163-SRCR5 domain
could be lifted. Further structure activity relationship (SAR) analysis has yet to be performed to
predict the docking site of B7 compound in porcine CD163-SRCR5 domain. We further verified
that B7 treatment does not inhibit virion binding (Figures 3.5.C, 3.5.D left) and internalization
(Figure 3.4.D right) to PAMs in vitro, suggesting that B7 compound does not target some
reported viral attachment factors, such as heparan sulphate and sialoadhesin (Delputte et al.,
2005). Our finding that treatment with B7 has its anti-PRRSV activity exclusively during the
post-inoculation period is consistent with the reported activity of porcine CD163 receptor in
PRRSV infection. Porcine CD163 receptor interacts with PRRSV GP2a and GP4 proteins and
mediates viral uncoating, which occur prior to virion binding and internalization to the host cells
(Van Gorp et al., 2008).
Despite tremendous efforts, no vaccines currently available are effective against
heterologous PRRSV strains. Developing alternative prevention approaches to vaccines are of
great interest. The inhibition of key PPIs between PRRSV and CD163 with natural or synthetic
compounds is a unique and promising approach to controlling the PRRS panzootic. B7
compound, screened by our BiFC assay, has not been documented previously in terms of its
biological activities. The finding that compound B7 as well as some of its derivatives
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substantially decrease PRRSV infection of PAMs in vitro (2-3 log10 infectious units) makes them
promising agents worthy of further investigation of their anti-PRRSV activity in pigs.
Additionally, Our study indicates that the inhibitory function of B7 and its analogues may
depends on the intact 3-(morpholinosulfonyl)anilino or the 3-(piperidinylsulfonyl)anilino moiety,
which provides further clues for developing more potent compounds against PRRSV infection
and minimizing the side effects of these compounds. This finding, combined with a full
understanding of the key residues in CD163-SRCR5 domain involved in PRRSV recognition,
would provide pertinent information for the targeted screening for effective compounds against
PRRSV.
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Figure 3. 1: Establishing BiFC assays and screening compounds that can inhibit the PPI
between PRRSV and CD163. (A) Schematic Diagram for the BiFC Assay Fusion Protein
Constructs between Pig CD163 SRCRs or PRRSV Minor Envelope Glycoproteins and the
Fragments of Venus Protein VN155(I152L) or VC155), Respectively. (B) Left: SRCR5-VN or
SRCR2-VN plasmids were co-transfected with GP2a-VC to HEK293T cells, with fluorescent
images taken at 24 h after transfection. Bar = 250 µm. Right: Cell fluorescence quantified by
ImageJ. Mean±SD. n=3. P values were calculated using paired t-test. An asterisk indicates a
comparison with the indicated control. **: p < 0.01. (C) Left: SRCR5-VN or SRCR2-VN plasmids
were co-transfected with GP4-VC to HEK293T cells, with fluorescent images taken at 24 h after
transfection. Bar = 250 µm. Right: Relative fluorescence intensity quantified. Mean±SD. n=3. P
values were calculated using paired t-test. An asterisk indicates a comparison with the indicated
control. **: p < 0.01. (D) Chemical structure of compound B7. (E) Left: BiFC assay between
SRCR5-VN and GP2a-VC proteins. Images showing positive inhibitory effect of compound B7
but not B8, with DMSO as the Ctrl. Bar = 250 µm; Right: Relative fluorescence intensity quantified.
Mean±SD, n=3. Means by the uncommon letter in each column are significantly different (p<0.05).
(F) Left: BiFC assay between SRCR5-VN and GP4-VC proteins showing similar inhibitory effect
by B7 compound but not by B8. Bar = 120 µm. Right: Relative fluorescence intensity quantified.
Mean±SD, n=3. Means by the uncommon letter in each column are significantly different (p <
0.05).

91

Figure 3. 2: Inhibition of PRRSV infection to PAMs by B7. (A) qRT-PCR for PRRSV in total
RNAs extracted from PRRSV strain VR-2332 infected PAMs treated with various concentrations
of B7 compound. Values are normalized with GAPDH of PAMs. Bars = mean±SD, n=3. PAMs
of the 3 repeats were from 3 donors. P values were calculated using Tukey’s post hoc comparison.
An asterisk indicates a comparison with the indicated control. ***: p < 0.001. (B) Titration assay
results for PRRSV in the culture media of PAMs treated as described in (A). Bars = mean±SD,
n=3. (C) qRT-PCR for PRRSV in total RNAs extracted from PAMs infected by different strains
of PRRSV and treated with 15 µM of B7 compound. Values are normalized with GAPDH of
PAMs. Bars = mean±SD, n=3. PAMs of the 3 repeats were from 1 donor. P values were calculated
using Tukey’s post hoc comparison. An asterisk indicates a comparison with the indicated control.
**: p < 0.01. (D) Titration assay results for PRRSV in the culture media of PAMs treated as
described in (C). Bars = mean±SD, n=3. **: p < 0.01.
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Figure 3. 3: Evaluating the PRRSV inhibitory effect for compounds structurally similar to
B7. (A) Molecular structures of B7 analogues (B7-A1 to A6) compared with B7. (B) BiFC assay
between SRCR5-VN and GP2a-VC proteins. Representative fluorescent images showing different
effects of compound B7 and its analogues on the PPI of SRCR5/GP2a, with DMSO as the Ctrl.
Bar = 250 µm. (C) Relative fluorescence intensity in (B) quantified by ImageJ. Mean±SD, n=3. P
values were calculated using Tukey’s post hoc comparison. An asterisk indicates a comparison
with the indicated control. **: p < 0.01, ***: p < 0.001. (D) qRT-PCR for PRRSV in total RNAs
extracted from PRRSV strain VR-2332 infected PAMs treated with 15 µM of B7 and its analogues.
Values are normalized with GAPDH of PAMs. Bars = mean±SD, n=3. PAMs of the 3 repeats were
from 1 donor. P values were calculated using Tukey’s post hoc comparison. An asterisk indicates
a comparison with the indicated control. ***: p < 0.001. (E) Titration assay results for PRRSV in
the culture media of PAMs treated as described in (D). Bars = mean±SD, n=3. *: p < 0.05, **: p <
0.01.
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Figure 3. 4: 3-(morpholinosulfonyl)anilino or 3-(piperidinylsulfonyl)anilino alone does not
inhibit PRRSV infection. (A) Molecular structures of B7-A7 and B7-A8. (B) Titration assay
results for the culture media of PAMs treated with B7, B7-A7, or B7-A8 and infected by PRRSV
strain V-2332. Bars = mean±SD, n=3. PAMs of the 3 repeats were from 1 donor. P values were
calculated using Tukey’s post hoc comparison. An asterisk indicates a comparison with the
indicated control. ***: p < 0.001, ns: non-significant.

Figure 3.4: 3-(morpholinosulfonyl)anilino or 3-(piperidinylsulfonyl)anilino Does Not
Inhibit PRRSV Infection and Post-Treatment with B7 Alone Inhibits PRRSV Infection. (A)
Molecular structures of B7-A7 and B7-A8. (B) Titration assay results for the culture media of
PAMs treated with B7, B7-A7, or B7-A8 and infected by PRRSV strain V-2332. Bars =
mean±SD, n=3. ***: P < 0.001. (C) qRT-PCR for PRRSV in total RNAs extracted from PAMs
infected by PRRSV VR-2332 and treated with 15 µM of B7 compound at pre and/or postinoculation. Values are normalized with GAPDH of PAMs. Bars = mean±SD, n=3. *: P < 0.05.
(D) Titration assay results for PRRSV in the culture media of PAMs treated as described in (C).
Bars = mean±SD, n=3. ***: P < 0.001.
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Figure 3. 5: B7 compound has its anti-PRRSV activity exclusively during post-inoculation
period. (A) qRT-PCR for PRRSV in total RNAs extracted from PAMs infected by PRRSV VR2332 and treated with 15 µM of B7 compound at pre and/or post-inoculation. Values are
normalized with GAPDH of PAMs. Bars = mean±SD, n=3. PAMs of the 3 repeats were from 3
donors. P values were calculated using Tukey’s post hoc comparison. An asterisk indicates a
comparison with the indicated control. *: p < 0.05. (B) Titration assay results for PRRSV in the
24hpi cell culture supernatant of PAMs treated as described in (A). Bars = mean±SD, n=3. ***: p
< 0.001. (C) The PAMs were pre-treated with DMSO as the Ctrl or 15 µM B7 for 4 h. Subsequently,
the cells were inoculated with VR-2332 or Lelystad PRRSV for 1h (MOI = 0.1) and were not posttreated before RNA was extracted from PAMs for RT-qPCR. Bars = mean±SD, n=3. PAMs of the
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also treated with DMSO as the Ctrl or 15 µM B7. Subsequently, the cells were frozen for RNA
extraction, or incubated without treatment for 24 h before RNA extraction. Bars represent mean±sd
of 3 independent experiments. PAMs of the 3 repeats were from 1 donor. P values were calculated
using paired t-test.
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Figure 3S. 3: MTT assay of the B7 compound incubated with PAMs for 24 h. scatter plots =
mean±SD, n=3. PAMs of the 3 repeats were from 1 donor.
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Ctrl or 15 µM B7 at 37°C for 1h. Then the viruses were directly used for virus titration. Since at
the endpoint of 50% of the cells were infected, the B7 had been diluted to extremely low
concentration alongside the viruses, the possible effect of B7 on PRRSV entry to the cells was
negligible. Therefore, the titration results appropriately represented PRRSV infectivity. Bars
represent mean±sd of 3 independent experiments. P values were calculated using paired t-test.
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Table 3. 1: B7 and B7 analogue compounds screened.
Designated
ID

Structure

Name

Molecular Formula: C25H24FN5O5S2
4-Fluoro-2-methyl-N-[3-(3morpholin-4-ylsulfonylanilino)
quinoxalin-2-yl] benzenesulfonamide

B7

Molecular Formula: C24H22ClN5O5S2
N-[3-(4-Chloro-3-morpholin-4ylsulfonylanilino)quinoxalin-2-yl]
benzenesulfonamide

B7-A1

Molecular Formula: C25H25N5O5S2
2-Methyl-N-[3-(4-morpholin-4ylsulfonylanilino)quinoxalin-2-yl]
benzenesulfonamide

B7-A2
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Molecular Formula:
C24H23N5O5S2
B7-A3

N-[3-(3-Morpholin-4-ylsulfonylanilin
o)quinoxalin-2-yl]
benzenesulfonamide

Molecular Formula:
C26H27N5O4S2
4-Methyl-N-[3-(3-piperidin-1ylsulfonylanilino)quinoxalin-2-yl]
benzenesulfonamide

B7-A4

Molecular Formula:
C19H20N4O3S
B7-A5

4-Methyl-N-[3-(morpholin-4yl)quinoxalin-2-yl]
benzenesulfonamide
Molecular Formula:
C19H20N4O3S
2-Methyl-N-[3-(morpholin-4yl)quinoxalin-2-yl]
benzenesulfonamide

B7-A6

Molecular Formula:
C10H14N2O3S

B7-A7

3-(morpholinosulfonyl)anilino
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Molecular Formula:
C12H17NO2S

B7-A8

N-P-tosylpiperidine

Table 3. 2: The sequences of primers used in this study.
Primers for qRT-PCRa
Lelystad-F

a

Sequence (5’ → 3’)
AAGATGACATCCGGCACCAC

Lelystad-R

CCGGCAGCATAAACTCAACCTG

VR2332-F

AAACCAGTCCAGAGGCAAGG

VR2332-R

GCAAACTAAACTCCACAGTGTAA

SDSU73-F

CCCTAGTGAGCGGCAATTGTGTC

SDSU73-R

GGCGCACAGTATGATGCGTC

NADC30-F

GGATGGCCAGCCAGTCAATC

NADC30-R

TGACGTCATCTTCAGTCGCTAGAG

GAPDH-F

CATCCTGGGCTACACTGAGG

GAPDH-R

GCTTGACGAAGTGGTCGTTG

F, forward primer, R, reverse primer.
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Chapter 4. Conclusion and Prospectus
PRRS is known to be one of the most economically significant disease across global
swine industry. Current MLVs only provide swine herd with efficient protection against
homogeneous PRRSV strains, but not genetically divergent strains. In this dissertation, we
identified some small molecules that inhibit PRRSV infection of PAMs in vitro, the primary
target of productive infection, by heterologous PRRSV strains. These screened chemical
compounds are alternative agents other than MLVs to potentially combat the PRRS panzootic.
In chapter 2, we demonstrated that interleukin 10 (IL-10) stimulated JAK/STAT3
signaling serves as a central signaling regulating expression of scavenger receptor CD163 in
PAMs. Out of 3 STAT3 inhibitors well documented in humans, we identified cryptotanshinone
(Cpt), a natural compound extracted from the herb Salvia miltiorrhiza (Danshen), was least
cytotoxic to PAMs and significantly downregulated IL-10-stimulated and basal level of CD163
expression. Subsequently, we characterized Cpt’s anti-PRRSV activity and showed that it was
able to efficiently inhibit PRRSV infection of PAMs by type I and type II PRRSV strains in
vitro. Some of the questions related to Cpt’s anti-PRRSV activity and worthy to be investigated
are listed below. 1) Considering Cpt is least cytotoxic to PAMs, would some antiviral effects still
be observed when the assay time is prolonged? 2) Furthermore, considering its potent effect on
immune modulation, it would be interesting to investigate the effect of Cpt on phenotypic change
of T lymphocytes and thus on cell-mediated immune responses in vitro: incubate PRRSVinfected monocyte-derived dendritic cells with or without Cpt treatment, and then co-culture
these infected cells with lymphocytes for a certain period (lymphocytes can be retrieved from

102

supernatant of PBMC cell culture since they are non-adherent); then percentages of Foxp3+
CD25+ T lymphocytes is measured by flow cytometry; activity of T regulatory cells induced by
PRRSV-infected dendritic cells is evaluated by determining the proliferation of PHA-stimulated
PBMC co-cultured with lymphocytes previously co-cultured with PRRSV-infected dendritic
cells.
In chapter 3, a list of compounds was predicted most likely to bind porcine CD163SRCR5 domain by a structure-based virtual screen program named artificial intelligence
molecular screen (AIMS). We further screened these compounds in cellular assays using an
established cell-based BiFC assay. We identified one active small molecule (4-Fluoro-2-methylN-[3-(3-morpholin-4-ylsulfonylanilino)quinoxalin-2-yl]benzenesulfonamide, C25H24FN5O5S2),
designated herein as B7, substantially disrupted PPI between PRRSV glycoproteins and CD163SRCR5 domain. We further found the disrupted PPI by B7 compound could lead to block of VR2332 PRRSV infection of PAMs, and that B7 compound protected PAMs against type I and type
II PRRSV strains in vitro. Later, we demonstrated some B7 analogues inhibited infection of
PAMs by VR-2332 PRRSV whereas the other analogues had no antiviral efficacy. By comparing
the chemical structures of these small molecules and linking their structural differences to their
antiviral performances, we proposed either 3-(morpholinosulfonyl)anilino moiety in B7
compound or the 3-(piperidinylsulfonyl)anilino moiety in a B7 analogue could be
pharmacophore important for controlling PRRSV infection. However, some questions are still
worthy of investigation in the future. 1) Perform structure activity relationship (SAR) analysis to
predict binding site of these active small molecules in the porcine CD163-SRCR5. 2) Conduct
ligand-based virtual screening for the proposed pharmacophores and obtain additional small
molecules for cellular assays. This could make identification of additional anti-PRRSV small
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molecules possible. 3) After all the cellular assays, we will have obtained quite a few active
small molecules with anti-PRRSV activity in vitro, it would then be interesting to pick a lead
compound for characterization of anti-PRRSV activity in pigs. First, investigate the compound
safety by scoring the lesions of different organs such as lungs, liver, kidney, and spleen of pigs
with compound injection. Then based on the compound half-life in pigs, dose pigs with the lead
compound repeatedly and intramuscularly prior to or post challenge with VR-2332, NADC30,
SDSD73 or Lelystad PRRSV via both intranasal and intramuscular routes. Measure the viral
loads in the serum of different days post inoculation and in the end post mortem examinations
are performed. Lung lesion scoring is done by people blinded to the treatment groups. Viral
loads in the lung lobe, tracheobronchial lymph nodes, spleen, and inguinal lymph nodes are
measured.
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